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Introduction: Intravenous gentamicin is frequently prescribed for the empiric treatment 
of early-onset sepsis in premature neonates1. The effective delivery of gentamicin may 
be influenced by infusion rate and flush volume2. Additional parameters affecting drug 
delivery kinetics may include route of administration, background infusion rate and drug 
measurement variability which we aimed to further quantify in this study.  
Methods: A self-administered questionnaire was completed by Dunedin hospital 
Neonatal Intensive Care Unit (NICU) nurses to investigate: the site of administration, 
comparing peripheral intravenous line (PIV) or umbilical venous catheter (UVC); and 
which would be used for a dose of gentamicin given two clinical scenarios describing 
babies of 24 and 32 weeks gestation. Secondary information was collected regarding 
flush volume. Intravenous infusions were then designed to simulate gentamicin delivery 
through UVCs with a constant background flow rate of 0.5 mL/hr. Intended doses of 
gentamicin (2 mg or 5 mg) in syringes were weighed before and after administration and 
given by bolus injection over 3-5 minutes followed by a flush of 0.9% saline (1 mL or 2 
mL). Samples were collected at 5 minute intervals for 1 hour and analysed by high 
pressure liquid chromatography. Additionally, congo red dye (1% w/v) was used to 
mimic the drug administration phase during one replication of each dose/flush volume 
combination. 
Results: There were 42 nurses employed in Dunedin NICU during the survey period, of 
whom 37 (88%) responded. For a 24-week gestation baby, 34 nurses (92%) would 
administer into the primary lumen (20 ga), containing 10% dextrose (0.5 mL/hr), 
compared to 3 (8%) who would use the secondary lumen (23 ga), containing parenteral 
nutrition fluid (2.1 mL/hr). For a 32-week gestation baby 35 nurses (95%) would 
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administer through the slow-flowing primary lumen. If a PIV was present this would be 
used preferentially by 35 nurses (95%) to reduce the risk of infection. Smaller flush 
volumes were documented following administration through the UVC compared with 
PIV (1.17-1.35 mL vs 2.4 mL at 24 weeks and 1.42-1.74 mL vs 3.2 mL at 32 weeks). 
Complete recovery of 2 mg and 5 mg intended gentamicin doses was observed following 
administration of both 1 mL and 2 mL flush volumes when administered via a UVC. Of 
the 2.15 mg administered dose recovered when a 1 mL flush is used, 85% (standard 
deviation, SD, 3.1%) was collected by 10 minutes and 93% (SD 1.4%) over the first 30 
minutes. When a 2 mL flush was given, 99% (SD 0.5%) of the 1.88 mg administered 
dose was recovered in 10 minutes. Following a 5 mg intended dose, 93 % (SD 3.4%) was 
recovered at 10 minutes and 97% (SD 2%) in 30 minutes after a 1 mL flush, compared 
to 99% (SD 0.6%) recovered at 10 minutes with a 2 mL flush. 
Conclusion: Variability in neonatal gentamicin pharmacokinetics may be attributable to 
a number of factors. Clinical variability in the route of intravenous delivery was 
documented by means of a survey. Experimental evidence showed that simulated 
gentamicin delivery by bolus injection into slow-flowing neonatal central lines resulted 
in >90% dose recovery at 1 hour. Additionally, variation in the volumes of drug and flush 
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Glossary of terms 
Clinical 
Early onset sepsis event: clinically suspected or proven infection in the first 72 hours 
after birth 
Extremely low birth weight (ELBW) : < 1000 grams 
Gestational age: number of days/weeks of completed in-utero growth 
Low birth weight (LBW): < 2500 grams 
Neonatal period: first 28 days after birth 
Post-conceptual age: gestational age plus postnatal age 
Postnatal age: number of days/weeks after birth 
Preterm delivery: < 37 weeks completed gestation 
Very low birth weight (VLBW): < 1500 grams 
Pharmacological 
Administered dose: Gentamicin dose as determined by HPLC gentamicin concentration 
derived from standard curve on each day of analysis 
Dead volume/dead space: volume of fluid contained within the tubing of the intravenous 
system 
Intended dose: Prescribed 2 mg or 5 mg dose of gentamicin in this study 
Measured dose: Volume of 10 mg/mL solution of gentamicin drawn up in experimental 
syringe, based on weight 
Minimum inhibitory concentration (MIC): the lowest amount of drug required to limit 
the growth of an organism 
Total parenteral nutrition (TPN): nutritionally-complete solution containing glucose, 




List of abbreviations 
Cmax: maximum concentration of an antibiotic 
CV: coefficient of variation 
IV: intravenous (usually referring to therapy or venous access device) 
mg: milligrams 
mL: millilitres 
NICU: Neonatal Intensive Care Unit 
PICC: Peripherally Inserted Central Catheter 
PIV: Peripheral intravenous line 
SD: standard deviation 
UVC: Umbilical Venous Catheter 





The use of medication for preterm babies is a frequent event in the modern neonatal 
intensive care unit (NICU), however the pharmacokinetics of drug administration are not 
well understood. This is a clinically focused dissertation and is principally concerned 
with the administration of gentamicin, an aminoglycoside antibiotic, in the NICU setting. 
Drug administration research in the neonatal population is extremely difficult and there 
is a paucity of evidence regarding the pharmacokinetics and efficacy of many medicines, 
despite their regular use. The following literature review will take the approach of 
introducing the population and clinical relevance of the topic first, followed by a 
discussion about drug administration in general and previous drug delivery kinetics work 
in the neonatal population and finally a section dedicated to gentamicin. A large number 
of questions remain unanswered in the area of neonatal drug administration, but this work 
hopes to contribute to an increasing understanding of the most effective method of 
administration and monitoring of gentamicin for the treatment of early-onset neonatal 
sepsis.   
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1.1 Neonatal morbidity and mortality 
With advances in neonatal care, the survival of premature infants has greatly improved 
in the last decades of the 20th century3. Premature babies are defined as those born before 
37 weeks completed gestation, though these can be subcategorised further into degrees 
of prematurity based on gestational age and birth weight. Babies born weighing <1000 g 
are classed as extremely low birth weight, those 1000 g-1499 g considered very low birth 
weight and 1500 g-2499 g is low birth weight. The average weight of a full-term male 
baby is 3.55 kg and a female is 3.4 kg . In this section the epidemiology of premature 
births in Australia and New Zealand will be discussed, followed by a general discussion 
regarding the aetiology and survival of these babies. The primary indication for 
gentamicin therapy in premature neonates is in the treatment of early-onset sepsis, which 
will be discussed in due course, along with the consequences of early infection in 
premature babies. The aim of this section of the literature review is to present the clinical 
relevance of this topic in the wider context of neonatal hospital care. 
1.1.1 Epidemiology  
The epidemiology of premature births in Australia and New Zealand is well documented 
in data collected by the Australian and New Zealand Neonatal Network (ANZNN), a 
collaboration of 28 Level III and 26 Level II neonatal intensive care units (NICUs) across 
these two countries. Babies are eligible for inclusion in this audit process if they are born 
at <32 weeks gestation or weighing <1500 g or received assisted ventilation (including 
mechanical ventilation and continuous positive airways pressure) for 4 hours or more, 
including those who died earlier than 4 hours while receiving ventilatory support, or 
babies who received major surgery or therapeutic hypothermia4. This care is generally 
provided at Level III NICUs for more specialised interventions, or Level II units where 
supportive and convalescent care is delivered. In the lower South Island of New Zealand 
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the Southern District Health Board provides Level III care at Dunedin Hospital and Level 
II at Kew Hospital in Invercargill.  
The most recent published ANZNN data set is from 20114, and contains epidemiological 
data regarding 7,412 Australian and 1,770 New Zealand babies who met criteria for 
inclusion. These births account for 2.5% of the total births in 2011 in Australia and 2.9% 
of births in New Zealand in that calendar year, of whom 40.6% of the Australian births 
and 29.9% of the New Zealand cohort were born before 32 weeks gestation4. There are 
an increasing number of births after each week of completed gestation up to 32 weeks, 
ranging from 0.6% of all ANZNN-registered births occurring at <24 weeks to 9.5% at 31 
weeks4. Similarly, birth weights rise with increasing gestational age. 
1.1.2 Aetiology 
The aetiology of premature birth can vary by gestational age and is largely unknown even 
though worldwide the rate of premature birth is increasing5. Overall rates of premature 
delivery are greatest in non-caucasian ethnic groups5 6 although again the mechanisms 
for this remains unclear. Maternal predispositions to premature delivery include a 
personal or family history of premature birth6 7; multiple gestation pregnancies7; maternal 
medical disorders such as thyroid disease, asthma, diabetes and hypertension7; and 
smoking8 9. Intrauterine infection is commonly described as predisposing to preterm 
birth10, possibly due to the activation of inflammatory cytokines and chemokines which 
lead to prostaglandin synthesis and subsequent stimulation of uterine contraction7. 
Cervical insufficiency has also been postulated as a predisposing factor, but the 
contribution that this makes to premature deliveries is uncertain3. Extremely preterm 
births (23+0 to 26+6 weeks) have been commonly observed due to idiopathic reasons, 
whereas births at late gestation (between 34 and 36 weeks) are more frequently due to 
medical indications for conditions such as pre-eclampsia and gestational diabetes5.  
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As well as maternal and obstetric reasons for premature delivery there are likely to be 
infant-related factors in the aetiology of this condition. For example, pregnancies affected 
by a single gene disorder such as neurofibromatosis, myotonic dystrophy, Ehlers-Danlos 
syndrome or Smith-Lemli-Opitz syndrome are at increased risk of premature delivery6. 
1.1.3 Survival rates 
Hospital discharge data from New Zealand and Australia is reported in the ANZNN audit, 
with 94.8% of registered babies born in 2011 surviving to discharge home after a median 
length of stay of 29 days (ranging from 6 days at 41 weeks completed gestation to 129 
days at 24 weeks)4. Mortality is highest in babies born at less than 27 weeks gestation 
compared with those born after this time (52.7% survival to discharge in babies born at 
<24 weeks completed gestation versus 97.5% survival in babies born at 29 weeks4). 
Increasing rates of survival to discharge home are also observed with increasing birth 
weight4. 
The long-term impact of premature birth must not be overlooked. Disability rates 
(including cerebral palsy, developmental delay, visual and hearing impairment) are 
approximately 20% in babies born weighing <1000 grams at any gestation and rates are 
highest in those born earlier than 25 weeks gestation11. These children are likely to have 
ongoing health and educational needs related to their prematurity and associated 
complications. There are also significant social and economic costs for the family related 
to the length of stay their babies require in NICU settings; an Australian paper from 2009 
estimated the financial burden to amount to 27% of the gross weekly income12 during 
their hospital stay. 
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1.1.4 Early onset sepsis 
One of the most frequent problems encountered by newborn premature babies is sepsis, 
which has a 3-10 fold greater incidence in preterm low birth weight babies than in those 
of full-term gestation13 and can have a significant effect on morbidity and mortality. 
Traditionally this is divided into episodes of early or late-onset sepsis, though both are 
variably defined in the literature. Early-onset sepsis events are most commonly defined 
as occurring in the first 72 hours after birth1 14 15 16 17 18 19 20 21but other definitions such 
as the within the first 48 hours after birth4 are sometimes used. Early-onset 
characteristically refers to the first significant infection that is encountered by a neonate, 
and can refer both to suspected and proven infections. In 2011 6.3% of ANZNN babies 
had an episode of  culture-proven early-onset sepsis, of which 72.6% occurred in those 
born at less than 32 weeks gestation4. This prevalence is higher than in other large studies 
from North America (1997–2010)17 and Taiwan (2005 – 2009)18 which report a 1% 
prevalence of early-onset sepsis, and Israel (1995–2005) who report a 2.4% risk of early 
onset sepsis in very low birth weight neonates15. In the next section the clinical 
manifestations and laboratory investigations for early-onset sepsis will be discussed, 
followed by the common causative organisms and treatments used in this condition. 
A. Investigations 
Episodes of sepsis can be clinically suspected, blood-culture proven or both. The signs 
and symptoms vary by gestational age and severity of infection and include non-specific 
findings such as lethargy, hypothermia (more commonly than fever); and poor feeding20. 
Investigations including laboratory tests and imaging are often initiated at the onset of 
suspicion of infection and empiric antibiotics are started promptly. Blood samples for 
culture, white blood cell count and differential and acute-phase reactants such as C-
reactive protein (CRP) are frequently requested, though microbiological identification of 
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bacterial pathogens on culture is often not known for hours or days after the sample has 
been obtained. As yet there is no definitive test which will predict culture-positive sepsis 
at an early stage, nor any that will rule it out14. Positive bacterial cultures (from blood, 
urine or cerebrospinal fluid) in addition to clinical suspicion determine whether an 
episode of sepsis is proven or not. Because respiratory signs such as tachypnoea are a 
common presentation of sepsis in the neonate a chest x-ray is often taken as part of the 
initial investigation into the underlying cause of an illness. Additional tests including 
abdominal x-ray, lumbar puncture, sterile urine collection, tracheal aspirate and samples 
from the tip of catheters such as umbilical lines or endotracheal tubes are performed 
according to the clinical presentation and timing of illness.  
B. Risk factors 
Risk factors for early-onset sepsis include maternal factors such as dietary intake of 
contaminated food (predisposing to Listeria monocytogenes), procedures during 
pregnancy such as amniocentesis and labour-related factors such as prolonged (>18 hour) 
rupture of membranes, fever and vaginal colonization with group B streptococcus20. 
Additionally, there are infant factors such prematurity, low birth weight, low Apgar 
scores, instrumental delivery and congenital anomalies which are also risk factors for 
early-onset development of sepsis20. Exposure to antenatal antibiotics and the need for 
mechanical ventilation on Day 1 were additionally shown to be significantly more likely 
to be associated with an episode of early onset sepsis (Odds Ratio, OR, 1.87 and 1.76 
respectively) in a North American study17.  
C. Common organisms 
The pathogens most commonly isolated from blood cultures in cases of early onset sepsis 
are gram positive group B streptococcus18 19 20 and gram negative Eschericia coli22, 
which are responsible for the majority of infections in term and preterm infants 
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respectively21. Additional pathogens to consider are Staphylococcus aureus and other 
Streptococcus species. The use of maternal prophylactic intrapartum antibiotics has 
reduced the incidence of early-onset group B streptococcal disease by 80%20, but despite 
this the incidence of early-onset sepsis has remained unchanged over time21. 
D. Treatment 
Empiric antibiotic therapy is frequently given to neonates early in their infective course, 
with rationalisation of antibiotic choices occurring when sensitivities of the isolated 
organism are known. Frequently, the combination of gentamicin with a beta-lactam 
antibiotic is used to provide synergistic activity against gram positive and gram negative 
bacteria23, and ampicillin or penicillin in combination with gentamicin have been shown 
to be equivalent1. There is a lower threshold for starting empiric antibiotic therapy in 
premature neonates when sepsis is suspected than term babies because of their immature 
immune system, vulnerable physiology, and potential for significant complications 
which will be discussed in section 1.1.5. A detailed description of gentamicin will be 
provided in section 1.3 as it is the use of this antibiotic for the treatment of early-onset 
sepsis that is fundamental to this dissertation. Gentamicin is a frequently used antibiotic 
in the Dunedin Hospital NICU, with 415 single use 20 mg/2 mL vials stocked by the unit 
in 201324. In this calendar year there were 250 admissions, 112 (45%) of them for preterm 
babies, but the number of babies who received gentamicin (either one dose or multiple) 
was not able to be determined from this data set. 
1.1.5 Complications of prematurity related to infection 
The significance of early onset infection in the neonatal population should not be 
underestimated. In the very low birth weight (VLBW) population, these infants are at a 
3-fold risk of death or major neurological morbidity15. Examples of the morbidity 
associated with early onset sepsis include grade 3 or 4 intraventricular haemorrhage 
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(Odds Ratio, OR, 2.24 compared to those without episodes of sepsis), grade 3 or 4 
retinopathy of prematurity (OR 2.04) and bronchopulmonary dysplasia (OR 1.74)15. 
Neonatal sepsis is also associated with an increased risk of chronic lung disease15, 
possibly from the increased ventilator-dependency of these premature babies during 
times of illness. In a 5-year follow-up study, the presence of both early and late onset 
sepsis events in VLBW babies was associated with an increased risk of cerebral palsy22. 
The pathological mechanisms underlying these complications of prematurity related to 
infection is not completely understood, but may include the response of the developing 
brain to an inflammatory insult25. 
Additionally, the consequences for the wider family and the health system can be 
considered as complications related to infection. For the family, there is commonly a 
restriction on their ability to hold (and hence to bond with) the baby when they are septic 
as neonates are often fragile on handling in these circumstances. It is difficult to quantify 
the impact that this has in the long term, but this is important to be cognisant of when 
nursing a sick premature baby in the NICU. Furthermore, the liberal use of antibiotics in 
extremely preterm babies is worth reflecting on, as the increasing antibiotic resistance of 
bacteria grows within our population and awareness of the importance of antibiotic 
stewardship becomes more apparent in the medical community. 
1.1.6 Summary 
Premature neonates are a vulnerable patient population whose clinical outcomes continue 
to be greatly enhanced by developments in modern technology. However, despite the 
most advanced equipment and environs, these patients remain susceptible to bacterial 
infections acquired in a multitude of different ways which require timely and effective 
treatment to ensure good outcomes. The consequences of not successfully treating early-
onset infections can be devastating, and so knowledge of predisposing factors and 
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causative organisms is important for preventing infection as far as that is possible to do, 
and an understanding of the most efficient way to use antibiotics wisely in this setting 
will be needed to eradicate the infection. While premature babies only account for a small 
percentage of births in Australia and New Zealand each year, they require a considerable 
investment of resources, finance and emotion to ensure they have the potential to thrive 




1.2 Principles of intravenous drug administration to neonates 
There are a variety of different methods for administration of medications to neonates. 
For the purposes of this dissertation only the intravenous (IV) route will be discussed, 
but other methods include oral, intramuscular, subcutaneous and rectal, each of which 
has their own set of unique challenges in this population. There are a variety of factors 
to consider when administering IV medications to neonates, including the placement and 
construction of the venous access device and tubing; the formulation and dilution of 
medications; and the ways in which alterations to other fluids or medications interact 
with the drug of interest. Many of the studies on which dosing recommendations are 
made for neonates are adult or paediatric-based, but there is an increasing body of work 
specifically related to neonatal drug delivery kinetics which will be discussed in due 
course. 
1.2.1 Venous access devices 
Placement of the intravenous line for drug administration is often a challenging task in 
extremely low birth weight premature babies. They have fragile skin, small vessels and 
physical access to the baby is difficult given the thermoregulation that is provided by 
incubators and radiant warmers, particularly in the hours after delivery. Intravenous lines 
can take the form of peripheral or central lines. Peripheral IV lines are inserted into veins 
in the hands, arms or feet of the child and are short (14 or 19 mm in length) (BD Insyte 
24GA, Singapore, used in Dunedin NICU). Central IV lines are intended to reach larger 
vessels located more central to the circulatory system. These can take the form of 
umbilical venous catheters (UVC), particularly in the first 24 hours, which can remain in 
situ for approximately one week; or peripherally inserted central catheters (PICC), 
inserted distally but with extended lengths of tubing which reach the central circulation. 
Central lines require confirmation of placement (ideally at the superior vena cava/right 
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atrial junction if placed in the upper extremities, or at the inferior vena cava/right atrial 
junction if placed in the lower extremities) with an x-ray due to their potential for 
complications (the most severe being myocardial perforation causing pericardial 
effusion, cardiac tamponade or arrhythmia), however technology is evolving to make this 
process more efficient, including the use of bedside ultrasound to confirm position of the 
tip of the catheter26. 
1.2.2 Intravenous tubing and connections 
The construction of IV tubing for neonatal lines is often overlooked when considering 
medication administration in the neonatal population. The potential space within the line 
or tubing is often referred to as the "dead volume"27 or “dead space”, and it can be a 
reservoir of drug or fluid which is able to be unintentionally administered28 29, or 
inadvertently not administered at all. This could result in a drugs continued 
administration despite the clinical effect no longer being required, or administration of 
the initial drug at a later time when the line is accessed to give another medication. The 
tubing used in neonatal IV infusion sets has been designed to minimise this dead volume 
of tubing29 and improvements continue to evolve over time. 
In regard to connections within the line, the configuration of the angle at which they 
attach (T or Y junction) and the angle of the primary infusion tubing can also have an 
impact on the delivery of medications in the NICU setting. Experimental evidence has 
shown poor mixing and retrograde flow when a coloured solution diluted with water is 
administered into a primary continuous fluid infusion of 10% dextrose with the T 
connector angled 15° upwards30 because of the difference in specific gravities  between 
the drug solution for infusion and that of the carrier fluid. Inline filters are used in the IV 
tubing configuration as a way to decrease the risk of phlebitis by firstly reducing the 
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potential for particulate matter to be infiltrated and secondly reducing the risks of micro-
organism contamination31, but these may also interfere with the delivery of medications. 
Additionally, drug adsorption onto components of the IV tubing is an important factor, 
an example of which is insulin binding onto the PVC tubing in neonatal infusion studies32 
resulting in deactivation of the drug. Similarly, amiodarone is recommended to be given 
through a set-up that is free of polyvinyl chloride (PVC) and does not contain diethyhexyl 
phthalate (DEHP) because of the risk respectively of drug adhering to the bag33 and 
plasticiser leaching from the infusion bag34.  
1.2.3 Formulation and dilution of medications 
There are few medications that are specifically formulated for administration to neonates. 
Because of this, dilutions of adult or paediatric medicines are frequently required when 
these are prescribed for preterm babies, some of which require serial dilution steps 
making the potential for error in calculations even greater. The preparation of medicines 
varies between units, but in most there will be at least some of this done by nursing staff 
working in the unit at the time a specific drug is required. Preparation of morphine has 
been shown to have a significantly greater variability in accuracy when completed in the 
NICU, in comparison to preparation in the pharmacy (19.2% vs 7.8% respectively for 
solutions outside of the acceptable error range of ±7.5%)35. This has been partly 
attributed to calculation errors and wrong volume measurements35. 
Similarly, in paediatric and general anaesthesia an error rate of 29% (drug doses outside 
the acceptable error range of ±10% in comparison with the declared concentration) has 
been found and the greatest errors are shown to occur with non-standard dilutions or 
when medications are highly diluted36. 
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Suggested improvements to the way that paediatric and neonatal medications are 
formulated include manufactured standard concentrations appropriate for neonates35 36, 
standardising IV infusion concentrations within units37 and standardising dosing 
protocols for common medications (such as gentamicin) between units38. 
1.2.4 Fluid dynamics  
The total daily fluid requirement of a neonate, which is then translated into mL/hour, 
varies depending on the postnatal age, weight and clinical condition of the baby, but 150 
mL/kg/day is considered necessary for growth13. Because of the dead space and slow 
flow rates of neonatal infusions, it can take longer than expected for medicines 
administered upstream to reach the baby, as has been shown by in vitro experiments of 
continuous gentamicin infusions delivered over 30 minutes to extremely low birth weight 
babies, where less than 60% of the intended dose would be received by a 0.5 kg baby 60 
minutes after the infusion was started2. Similarly, if changes are made to the flow rate of 
a continuous infusion, including stopping the infusion, this also may take longer to 
register at the patient-end of the line than anticipated, especially at slow flow rates39. 
These considerations are especially important for clinicians to be cognisant of when 
medications such as inotropes are being administered.  
Also worth considering is the composition of the primary fluid that is being infused and 
the effect that mixing this with a drug being administered intermittently will have. The 
compatibility issues between these might give rise to problems such as precipitation or 
inactivation, drug trapping or retrograde flow29 30. 
One way to ensure the stable, forward flow of neonatal intravenous infusions is with the 
use of anti-reflux valves. At low adult flow rates, when the carrier fluid is being driven 
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by gravity rather than a pump, these have been shown to improve drug delivery by 10% 
at 10 minutes when compared with faster flow rates and no anti-reflux valve40. 
1.2.5 Current understanding of drug delivery kinetics 
There is a paucity of specific information regarding IV medication delivery to neonates, 
but some recent in vitro studies have attempted to explain this with respect to gentamicin 
in particular. Table 1 summarises experimental work completed at the University of 
Otago regarding gentamicin administration in the NICU.  
Different background carrier fluid rates have been investigated in simulated experiments 
designed to approximate neonatal clinical scenarios. The carrier fluid rate is determined 
by the chronological age and weight of the baby and experiments have been based on 
flows of 180 mL/kg/day for ELBW (500 g) and LBW (2.5 kg) babies. These experiments 
assume that the medication is given into a venous access device which concurrently has 
the nutrition-containing fluid running, such as when only one lumen is available (single 
lumen PICC) or when only a single PIV line is in situ. The composition of the carrier 
fluid has also been investigated, with 10% dextrose commonly used as a proxy for TPN 
solution. Primary infusion solutions of a different specific gravity to the drug solution 
were also investigated and retrograde flow (away from the patient) seen more frequently 
when the glucose concentration was 20% w/v30. 
Different flush volumes of 0.9% sodium chloride (saline) were also used during these 
experiments which found that the smallest babies (with the smallest corresponding doses) 
were not likely to receive all of their intended dose within 1 hour due to the slow primary 




Drug administration through different venous access devices (peripheral or central lines) 
has been considered over the course of these studies. As no direct comparison between 
the proportions of gentamicin recovered when it is administered by different methods has 
yet been made, there is no strong evidence to direct recommendations for clinical 
practice. This is an important consideration as the location for administering a dose of 
gentamicin may affect the measured peak and trough levels, and hence have implications 
for dose adjustments in NICU. 
It has been shown in these circumstances that lower carrier flow rates, given to smaller 
babies as a result of their limited fluid requirements, resulted in slower delivery of 
gentamicin than when a corresponding dose was given to a larger baby who received a 
faster background infusion rate. Continuous infusions of medication resulted in less of 
the dose recovered when given to ELBW neonates, but complete recovery of both small 
and large doses when the medication was given as a bolus instead. There was increased 




Table 1: Neonatal gentamicin pharmacokinetic studies 
Year of study (and method 
of drug administration) 
Carrier flow rate Gentamicin dose (volume) Flush volume (0.9% NaCl) Significant results 








2 mg (0.2 mL) 
 
 
5 mg (0.5 mL) 
 
 
1 mL at drug administration 
site over 5 mins 
or 
0.5 mL at site and 0.5 mL 
further upstream 
 At 2 mL/hr: 74-87% of 
drug was delivered at 10 
mins; 95-97% delivered 
at 30 mins 
 At 10 mL/hr: 97% of 
drug delivered at 10 
mins 
201230 (PIV, bolus injection 







2 mg (0.4 mL) 
 
10 mg (1 mL) 
 
1mL over 5 mins  
or 
1 mL over 30 mins 
or 
2 mL over 5 mins 
or 
3 mL over 45 mins 
 30 min infusions 
resulted in <30% of 2 
mg drug dose recovered 
during the infusion but 
at a higher dose and flow 
rate 80-90% recovery 
was seen during the 
infusion 
 Complete dose recovery 
(2 mg and 10 mg) seen 
when bolus doses were 
given over 5 mins 







0.5 mg (0.2 mL) 
 
2 mg (0.2 mL) 
 
2.5 mg (1 mL) 
 






Over 35 mins 
 
 Larger neonates had a 
higher percentage of 
administered dose 
recovered at 60 and 75 
mins compared to 
ELBW babies 
 2.5 kg neonates received 
only 80% of the 
intended dose by 60 
mins, increasing to 90-
95% at 75 mins 
 Increased dose recovery 




Administration of IV medications to neonates is a complex and incompletely understood 
aspect of neonatal care. This route is commonly used for medication delivery in the NICU 
and for preterm babies who are unable to tolerate enteral feeding for a variety of reasons, 
the IV route fully sustains them. The devices and tubing through which fluids are 
administered are important to consider, both in terms of the volume of fluid within them 
and the materials that they are constructed from, as both can have an impact on the drug 
of interest and the clinical condition of the baby. Similarly, the dynamics of fluid flow 
within this tubing are an important parameter to be aware of so that medication delivery 
can be optimised in these extremely premature babies. The standard manufacturing of 
medications for adult and sometimes paediatric patients results in a frequent need for 
dilution, reconstitution and preparation for their use to be translated into the NICU, 
thereby creating the potential for dosing errors or ineffective medicines. Work has started 
already with the aim of better understanding gentamicin drug delivery kinetics in 





Gentamicin is an aminoglycoside antibiotic which was first developed in the 1940s “by 
screening soil actinomycetes for antibiotic activity”42. It has the advantages of being low 
cost, chemically stable and with low potential for developing resistance42. However, due 
to its narrow therapeutic window requires more investigation before optimal use in the 
neonatal population can be firmly established. This section firstly introduces the 
principles of pharmacokinetics and pharmacodynamics with respect to gentamicin, 
including the added pharmacokinetic parameter of the drug delivery system in neonates, 
and then progresses to discussion regarding indications, dosing recommendations, 
adverse effects and therapeutic drug monitoring. There has been a lot of work done 
regarding gentamicin therapy in older populations but firm evidence of its specific use in 
premature neonates is sparse, although its use remains almost universal. 
1.3.1 Pharmacokinetics 
Pharmacokinetics describes the movement of drugs into and around the body. The 
pharmacokinetic properties of gentamicin include distribution and elimination, which are 
affected by infusion rate and have the potential to change significantly with age. In the 
neonatal population these parameters are complex and much of the current body of 
knowledge is a reflection of adult studies which have been extrapolated into younger 
populations. For the purposes of this work only intravenous administration of gentamicin 
will be considered, although in addition to a solution which can be administered by the 
intravenous, intramuscular and intrathecal routes it is also available as a cream, liquid 
and ointment for topical, ophthalmic and otic (auricular) administration, as well as a bone 
cement. 
Although assimilation of gentamicin is 100% when given by the IV route, the process of 
drug administration is important to consider. In the case of neonates, the tubing and 
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connections within the intravenous delivery system contain a significant dead space 
volume in comparison to the size of the baby and several different fluids and medications 
are frequently given simultaneously. The method of delivery of gentamicin to neonates, 
whether via central line or peripheral IV line is not often considered as a pharmacokinetic 
parameter, but does have a significant impact on the amount of drug that is successfully 
administered, especially in low birth weight babies. This is illustrated by Sherwin et al., 
where it was shown that in extremely low birth weight babies only 60% of the intended 
gentamicin dose was recovered from the end of a simulated intravenous line after 60 
minutes2. Additionally, work has been done which shows the effect that the angle of 
connections within the tubing has on the direction of anterograde or retrograde flow of 
the infusion, and also the effect of different fluid densities on the successful 
administration of medications given intravenously30. 
Absorption following intravenous administration of gentamicin is considered to result in 
peak serum concentrations in 30-60 minutes in adults and older children43, but this time 
frame is yet to be confirmed in the neonatal population, particularly premature neonates. 
Distribution is concerned with the dispersion of gentamicin throughout body 
compartments – that of blood stream where it is administered, and to the primary site of 
action in the tissue compartment. The volume of distribution varies with age, and for 
water soluble drugs such as gentamicin it is significantly larger in neonates than adults 
as they have a proportionally greater body water content44 and immature renal function43. 
In the case of septic neonates this volume of distribution increases further still, possibly 
because of fluid retention, interstitial oedema and capillary leakage45. 
Gentamicin is renally eliminated. This is important to consider in the context of the 
relative renal insufficiency of premature neonates at birth, though renal function as 
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determined by glomerular filtration rate improves rapidly thereafter46. Additionally, 
gentamicin is often prescribed on the first day of life when renal function is unknown, as 
serum creatinine is more reflective of the mother’s renal function than the child’s at this 
time. This poses unique problems in this vulnerable population and results in dosing 
recommendations being made based on gestational age, post-conceptual age (gestational 
age plus postnatal age) and weight as these have the best predictive capacity for clearance 
in premature neonates47. 
1.3.2 Pharmacodynamics 
The pharmacodynamic properties, as well as describing the effect of gentamicin on the 
body, relate to the drug’s effects on the bacteria that they are prescribed to treat. 
Gentamicin is a bactericidal aminoglycoside antibiotic and exerts its effects on the 30s 
ribosomal subunit of bacterial cells, resulting in impaired protein synthesis. Gentamicin 
works synergistically with the beta-lactam antibiotics it is commonly prescribed with, as 
these disrupt the bacterial cell wall making it easier for gentamicin to reach its site of 
action.  
The relationship of gentamicin to bacteria, in particular to the minimum inhibitory 
concentration (MIC, the lowest amount of drug required to limit the growth of an 
organism) of each organism, is another essential pharmacodynamic factor to consider. 
When dosing concentration-dependent drugs such as aminoglycosides, the ratio of 
maximum concentration of antibiotic (Cmax) to MIC (Cmax/MIC) and the area under the 
concentration-time curve over a 24 hour period (AUC0-24) are important PK/PD 




1.3.3 Indications and dose recommendations 
Gentamicin is indicated and commonly used for the treatment of suspected or proven 
neonatal sepsis, as discussed in section 1.1.4 Part D. It has wide gram negative coverage, 
including activity against E. coli, Pseudomonas, Klebsiella and Serratia species as well 
as activity against gram positive organisms such as Staphylococcus. Gentamicin is 
widely used in neonatal units across New Zealand and Australia as first line treatment 
for early onset sepsis, in conjunction with a beta-lactam antibiotic, though there is no 
consensus on the most appropriate dose or monitoring protocol and a wide variety of 
different regimes are in use currently51, as is also the case in the UK38.  
It has now been established that extended interval dosing is safe and effective in the 
neonatal population as compared to the previous multiple daily dosing schedule42 52 53. 
This dosing regimen has benefits that include the ability to achieve higher peak 
concentrations (thus greater concentration-dependent bactericidal activity), along with 
being able to maximise the post-antibiotic effect of gentamicin, which is the continued 
ability to suppresses bacterial growth after concentrations drop below the MIC of the 
organism48. With a longer dosing interval there is also less potential for toxicity, as the 
trough concentrations are able to fall to an appropriately low level, and the development 
of adaptive resistance is minimised. Adaptive resistance occurs as the bacteria become 
more exposed to a particular antibiotic and are able to down-regulate transport of the 
antibiotic into their cells42, but it is thought that this ability decreases with a longer time 
interval between doses. However, individualised dosing, including extending the dosing 
interval is possibly a more reliable strategy for infants born at less than 32 weeks 
gestation53. In this way Alshaikh et al. based the dosing interval for an extended-interval 
dosing schedule on levels at 22 hours in infants <28 weeks gestation and showed that this 
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was able to achieve higher peak levels and no increase in trough concentrations when 
compared with traditional dosing54.  
The current recommendations in Dunedin hospital are based on the Neofax® 2011 
guidelines33 and are dosed according to Table 2, varying by gestational age, postnatal age 
and body weight. 













Determined by level at 
24 hours: 
See below 




>35 ALL 4 
 
Dose interval is determined by drug levels at 24 hours according Table 3 and peak and 
trough levels are monitored after the first and third doses. 
Table 3: Dunedin Hospital NICU gentamicin dosing interval55 
  
Level at 24 hours Dose Interval 
<2mcg/mL 24hr 
2.1 - 3mcg/mL 36hr* 
3.1 - 4mcg/mL 48hr* 
>4mcg/mL Consider alternative antibiotic e.g. 
cefotaxime  
* If interval >24h, discuss with paediatrician whether an alternative antibiotic is 
required  
 
In many units, it is standard practice to administer gentamicin intravenously over a 30-
minute infusion time. However, administration by bolus injection has been shown in in 
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vitro studies to result in a greater proportion of gentamicin being recovered when 
prescribed in extremely low birth weight babies when compared with administration by 
continuous infusion2, thus it is administered as a slow IV push over 3 – 5 minutes in 
Dunedin NICU. 
1.3.4 Adverse effects 
In 1972 the World Health Organisation defined an adverse drug reaction as any response 
to a drug which is “noxious, unintended and occurs at doses used in man”56. The two 
potentially significant adverse effects of gentamicin are nephrotoxicity and ototoxicity, 
which predominantly occur due to impaired clearance, resulting in an accumulation of 
the drug in the patient. In a 2011 Cochrane review comparing once daily dosing with 
multiple doses per day of gentamicin there were no nephrotoxic results seen in either 
group and no statistically significant difference in auditory toxicity found53. 
Nephrotoxicity develops predominantly as the result of accumulation of gentamicin in 
the proximal tubules of the kidney, inducing cellular apoptosis and necrosis, but can also 
occur due to reduced glomerular filtration by induction of mesangial contraction in the 
glomerulus, and reduced renal blood flow due to increased vascular resistance in the renal 
vascular bed57. The observed physiological manifestations of this nephrotoxicity are 
described as non-oliguric renal failure with a decrease in glomerular filtration rate as 
measured by creatinine clearance58. Based on adult studies Wargo et al. argue that the 
empiric use of aminoglycosides for less than 7 days has minimal risk of nephrotoxicity, 
especially when extended interval dosing and therapeutic drug monitoring are used57. 
The cumulative effects of gentamicin resulting in nephrotoxicity are thought to arise from 
high trough concentrations due to accumulation of high concentration of the drug in the 
tissues59, and thus checking serum levels before the administration of the next dose, once 
steady state has been established, is an important practice. Nephrotoxicity is also felt to 
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be more of an issue when gentamicin is prescribed concurrently with other nephrotoxic 
drugs such as furosemide. The renal impairment that can be noted on routine blood 
monitoring is considered reversible on stopping the nephrotoxic drug(s)33. 
Conversely, ototoxicity, is irreversible and harder to screen for. This is felt to develop as 
a result of free radical production and damage to cochlear and vestibular hair cells60. The 
cochlear cells that are damaged first are associated with high-frequency hearing loss, and 
though audiology screening is done as part of the newborn hearing testing before an 
infant leaves the NICU, it is often difficult to know what the clinical significance of 
findings is, particularly if they are mild, until months or years later as the childs language 
development progresses. A Christchurch study found no evidence of any increased risk 
of hearing impairment in neonates treated with gentamicin for early onset sepsis over a 
5 year period61; nevertheless ototoxic drugs remain a risk factor which is highlighted in 
the universal newborn hearing screen. Another risk factor for the development of 
sensorineural hearing loss is the presence of a mitochondrial A1555G mutation62, 
suggesting that care should be taken when prescribing aminoglycosides to babies in 
whom a family history of progressive hearing loss exists42. The vestibular effects of 
gentamicin toxicity are more subtle and include symptoms such as balance disturbance, 
visual disturbance and tinnitus63. Gentamicin is felt to be more vestibulotoxic than 
cochleotoxic, and the risk of toxicity increases with duration of exposure to the drug 60, 
though no current screening test exists to detect this potential damage in newborns.  
1.3.5 Therapeutic drug monitoring 
The purpose of therapeutic drug monitoring is to monitor the efficacy and toxicity of 
gentamicin. The peak serum concentration is used as a proxy for tissue concentration and 
clinical efficacy correlates well with this level43. A Cmax/MIC ratio of 8-10 is targeted to 
ensure maximum bactericidal activity43, 50 as a Cmax/MIC ratio of >10 has been shown to 
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have an Odds Ratio of response to treatment of 8.41 (as compared to Odds Ratio of 
response to treatment of 1.83 when a Cmax/MIC ratio of 4-6 was targeted
42). In order to 
get accurate measurements of the peak concentration, it is imperative that 
pharmacokinetic aspects such as drug administration are accurately understood. Thus far, 
assumptions have been made for neonates based on extrapolated data from adults, and 
peak levels are routinely taken 30 to 60 minutes after the drug is administered43. Whether 
this is an accurate reflection of the true serum peak concentration of gentamicin in 
neonates remains to be seen.  
Trough levels are felt to reflect the potential to develop toxicity as a result of gentamicin 
accumulation. These are traditionally taken ½ hour before the next dose is due, and the 
practice in Dunedin NICU is to withhold the dose until the trough level is <2 µg/mL. 
With changing the dosing recommendations from traditional interval dosing to extended 
interval dosing there have been a number of studies comparing gentamicin dosing 
schedules in premature babies which have generally shown that low birth weight babies 
receiving a high dose every 48 hours attain therapeutic peak levels and low trough 
concentrations 64 and are therefore safe to use. 
Steady state concentrations are traditionally considered to exist after 4 half-lives of the 
drug have passed44 which, in the case of gentamicin, is generally accepted as after the 
third dose. Though therapeutic drug monitoring usually occurs around this dose, it is the 
experience of practitioners at Dunedin NICU that considerable variability exists in 
aminoglycoside pharmacokinetics in neonates2 50 65 so levels for therapeutic drug 




Gentamicin is a frequently used antibiotic in the NICU setting. Its traditional 
pharmacokinetic and pharmacodynamic properties are well understood in the older 
population, but in neonates there is more still to be learned. Additionally, the different 
methods of IV gentamicin delivery (peripheral or central line; differences in flow rate, 
type of primary infusion fluid; and volume of flush) are likely to result in further 
alterations to the pharmacokinetics of the drug in this population. Gentamicin toxicity 
and efficacy correlate with measurements of trough and Cmax concentrations respectively. 
In these circumstances, the trough concentration is useful for therapeutic drug monitoring 
to prevent adverse effects such as nephrotoxicity and ototoxicity occurring, but further 




1.4 What is not known about this topic 
Gentamicin for intravenous administration in the treatment of early-onset neonatal sepsis 
is well established, though there are many aspects of its use that are incompletely 
understood. Currently a range of dosing and monitoring protocols exist, which is likely 
a reflection of the paucity of evidence in the literature regarding the administration of 
this antibiotic. This is especially true in the case of extremely preterm neonates where 
PK/PD parameters are different from those in the older paediatric and adult populations.  
The following are examples of knowledge gaps in the administration of gentamicin in 
the NICU setting: 
 The dose in mg/kg needed to consistently achieve a therapeutic peak 
 Target Cmax and Cmax/MIC ratio 
 The most appropriate location to give a dose of gentamicin (PIV, UVC or PICC) 
and where in the intravenous architecture to administer this dose 
 The size of the flush to give following a dose of gentamicin 
 The effect that very slow flow rates have on drug delivery 
These factors need research evidence and clinical correlation before a robust dosing and 




1.5 Objective of this research 
The overall objective of this research project is to understand the influence of background 
infusion rate and flush volume on recovery of gentamicin when it is administered by 
UVC to premature neonates and to compare this to PIV administration of gentamicin in 
NICU. 
1.5.1 Specific aims: 
1. To investigate the current neonatal nursing practice for UVC administration of 
gentamicin in the first 48 hours after birth and to determine the size of the flush 
volume administered following the medication. 
2. To describe what flush volume is needed to recover the entire gentamicin dose 
when it is administered as a bolus through a peripheral IV line. 
3. To find out how long it takes a dose of gentamicin to be given in its entirety when 
administered into a UVC with a slow flowing background infusion rate. 
4. To appreciate what percentage of a dose of gentamicin is delivered 1 hour after 
administration through a UVC with different flow-rates. 
It is beyond the scope of this dissertation to use the information gained here to predict 
the appropriate time for measuring peak serum gentamicin concentrations in premature 
babies, but it is hoped that this work will be used in conjunction with previous studies to 
contribute to this model development. In time the information gained here will be used 




2.0 Chemical compounds 
The antibiotic for injection was gentamicin 20mg/2mL Pediatric injection vial (APP 
pharmaceuticals, USA) followed by a flush of 0.9% sodium chloride [NaCl] (Ajax 
Finechem, New Zealand). The internal standard was tobramycin (Sigma-Aldrich, China), 
and standard curve was prepared from gentamicin sulphate (Sigma-Aldrich, China). The 
derivatisation reaction was completed with boric acid [H2BO3] (Ajax Finechem, New 
Zealand), sodium tetraborate [Na2B4O7] (Ajax Finechem, New Zealand), 9-
fluorenylmethyl chloroformate [C15H11ClO2] (Fluka, Switzerland) and glycine 
[NH2CH2COOH] (BDH AnalR, England). The mobile phase was 90% acetonitrile 
(HPLC grade LiChrosolv, Germany) in distilled deionised water (MilliQ, 18.2 Ohms), 
degassed by vacuum filtration through a 0.45 µm filter. 
2.1 Clinical equipment 
The following is a description of the clinical equipment used for the simulation 
experiments, identical to the Dunedin NICU setup. CareFusion NZ are gratefully 
acknowledged for their loan of the Alaris® GH plus pump.  
The peripheral IV line was 24GA 0.75IN BD Insyte ™ IV catheter (BD, Singapore) and 
the UVC was 3.5Fr 15IN polyurethane dual-lumen umbilical vessel catheter (Tyco 
Healthcare, USA). The components of IV tubing were SmartSite ® Needle-Free Valve 
Port (CardinalHealth), Baxter Interlink System T-connector extension set (Baxter 
Healthcare Corporation USA), Safti-ject SV® (Mini bore leur lock extension set with a 
Safti-ject SV® swabable valve needleless connector and a back check valve and 0.2 
micron air eliminating filter)(CODAN US Corporation for REM Systems Ltd, New 
Zealand). This was plugged for the PIV experimental series, and attached to a 140 cm 
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minimum volume extension tubing (B. Braun, Germany) connected to an Alaris® GH 
plus pump (CareFusion) for the UVC experiments. Dextrose 10% (Baxter, Australia) was 
the primary fluid in the tubing. Syringes used for administration of gentamicin and 0.9% 
saline flush were 1 mL leur lock tip (BD, Singapore) and 5 mL leur lock, latex free (BD, 
Singapore) respectively. 
2.2 Laboratory equipment 
Samples were collected in 1.7 mL microtubes (Axygen, USA) or 5 mL polypropylene 
screw top tubes (Sarstedt, Australia). Dilutions and preparation for HPLC analysis was 
made using eppendorf pipettes and 200 µL and 1000 µL pipet tips (Axygen, USA). 
A SHIMADZU HPLC instrument was used. This consisted of a RF-10Axl fluorescence 
detector (ƛexcitation 260 nm, ƛemission 315 nm), CTO-20A column oven (set at 30°C), 
SIL-20AC autosampler, LC-20AD liquid chromatograph and DGU-20A5 degasser. The 
column was a C18 (2) Luna, 4.6 mm x 150 mm, particle size 5 microns, pore size 100 
angstroms. Flow rate was 1 mL/hr. The HPLC mobile phase was 90% acetonitrile in 
distilled deionised water, degassed by vacuum filtration through a 0.45 µm filter and 
administered with a gradient system. 
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3 Method Part A: Neonatal nurses survey 
3.1 Overview 
Part A of this project was completed with the purpose of gaining baseline information about 
how gentamicin was currently being given in clinical practice. Previous work in this 
department2 30 41 has simulated gentamicin delivery using a variety of different approaches as 
discussed in section 1.2.5, but for this current work to be clinically relevant it was felt that the 
next set of experiments should reflect contemporary clinical practice. Reflection on current 
nursing care practice will also be useful as a baseline for the development of a ‘best practice’ 
approach to gentamicin administration for premature neonates. 
3.2 Study design 
A questionnaire (Section 6.2) was designed with guidance from medical and research nursing 
staff in the Dunedin NICU. This was a self-administered written survey and responses were 
recorded anonymously. There were a range of question types, with multi-choice, free text 
written and numerical information sought. 
Ethics approval was discussed but not formally requested due to the quality improvement 
nature of this work, and no reference to patient notes or direct impact on patient care occurred.  
3.3 Participants 
All nurses working at Dunedin NICU were invited to participate, in writing and verbally, by 
the primary investigator and associate charge nurse manager on each shift. Discussion was 
permitted within the nursing team and reference to the unit drug administration protocol 





The primary aim was to determine which lumen of a double lumen umbilical venous catheter 
(UVC) would be used for administration of gentamicin to a premature baby in the first 24 – 48 
hours after birth as depicted in Figure 1. 
 
Figure 1: Double lumen umbilical venous catheter  
with thanks to A/Prof Natalie Medlicott 
The primary lumen contained an infusion of total parenteral nutrition (TPN) and lipid at a rate 
of 90 mL/kg/day (minus 0.5 mL/hr to account for the fluid running through the second lumen) 
and the second lumen contained 10% dextrose at a consistent rate of 0.5 mL/hr as is standard 
practice in this neonatal unit. Locations for bolus drug administration were labelled B on the 
primary lumen and A on the secondary lumen. 
Secondary information regarding the flush volume of normal saline that would be given 
following the dose of gentamicin at different sites of administration (both on the UVC and also 
when given peripherally) was also collected.  
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3.5 Survey questions 
Three questions were asked in the survey in order to determine where a dose of gentamicin 
would be given to a premature baby in their first days of life. Two different scenarios – that of 
an extremely low birth weight baby (700 g, which is on the 50th centile for babies born at 24 
weeks gestation) and a low birth weight baby (1800 g, on the 50th centile for babies born at 32 
weeks gestation) – were used as clinical examples. The total fluid volume of 90 mL/kg/day 
was chosen as the baseline flow rate because it represents a common fluid prescription for 
premature babies in the 48 hours after birth.  
In the first question (Figure 2) only the option of using the UVC for administration of 
gentamicin was offered. 
 
Figure 2: Survey question 1 
In the second question, nurses were asked whether the presence of a peripheral IV line in 
addition to the UVC would alter the answers they gave in the first question. A free text response 
was invited to allow them to expand on reasons behind these answers. 
The third question asked for the nurses to fill in the table below with the volume of 0.9% saline 




Table 4: Survey question 2 - flush volumes 
Case Plugged peripheral 
intravenous line in 
situ 
Gentamicin bolus 
dose given at point 
A 
Gentamicin bolus 






























Results of the data received were analysed using Microsoft Excel 2013. They have been 
discussed by departmental medical and research staff in addition to presentation and discussion 
with neonatal unit nursing staff. Future practice may be informed by the results of experimental 




3 Method Part B: Experimental Work 
3.7 Overview 
The second part of this project intended to more fully explore the influence that flush 
volume and flow rate had on the amount of gentamicin that was successfully delivered 
to a premature baby. Two studies were designed to illustrate the recovery of gentamicin 
when it was delivered into a peripheral IV line and when the same dose was delivered 
into an umbilical central line (UVC). Analysis of these simulation experiments was 
completed in the laboratory using reverse-phase high pressure liquid chromatography. 
3.8 Study design 
Two experimental studies were designed, based on the results of the aforementioned 
NICU nurses questionnaire and with previously performed studies2 30 41 as a model. Both 
experiments were run in the laboratory and based on a set-up of how gentamicin would 
be administered intravenously to premature infants in the Dunedin Hospital NICU. 
The first of these experiments was designed to simulate gentamicin given via a peripheral 
intravenous line (PIV) and the second with a central line (an umbilical venous catheter, 
UVC). Different flush volumes were used within each experiment to compare the effect 
that this had on the percentage of the intended dose of gentamicin that was recovered in 
each series of experiments. The first simulation was completed to ascertain what flush 
volume was needed to recover the entire gentamicin dose when administered through a 
peripheral IV line. The second simulation was designed to appreciate what percentage of 
a dose of gentamicin was delivered over 1 hour after administration through a UVC with 




The aim of both parts of this experimental study was to ascertain whether different flush 
volumes affected the proportion of gentamicin dose recovered after administration 
through a simulated intravenous line. 
3.10 Preparation of stock solutions 
The following solutions were prepared and used for gentamicin analysis as described in 
section 3.12: 
 Gentamicin sulphate stock solution (1 mg/mL): 5 mg gentamicin sulphate powder 
was dissolved in deionised water to 5 mL using a volumetric flask. Aliquots of 1 
mL were transferred into eppendorf tubes and stored at -20 °C. 
 Internal standard: Tobramycin (0.5 µg/mL): 1 mg tobramycin powder was 
dissolved in deionised water to 1 mL using a volumetric flask. This stock solution 
was diluted to a working solution in stages by: 50 µL of 1 µg/mL solution diluted 
to 1000 µL with deionised water (=50 µg/mL), then 100 µL of 50 µg/mL solution 
diluted to 10 mL with deionised water (=0.5 µg/mL). Stored in fridge at 4 °C. 
 9-Fluorenylmethyl chloroformate (FMOC-Cl) (2.5 mM in acetonitrile): 12.935 
mg FMOC-Cl (MW 258.7 g/mol) powder was dissolved in acetonitrile to 20 mL 
using a volumetric flask. Stored in fridge at 4 °C, protected from light. 
 Glycine (0.1 M): 150.14 mg glycine (MW 75.07 g/mol) powder was dissolved in 
deionised water to 20 mL in a volumetric flask. Stored in fridge at 4 °C. 
  Borate buffer (0.2 M, pH 8.9): 50 mL solution A + 42.5 mL solution B, diluted 
to 200 mL with deionised water. pH confirmed 8.9 
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Solution A: 0.2 M boric acid (MW 61.83 g/mol = 61.83 g/1000 mL): 1.24 g 
boric acid powder diluted to 100 mL with deionised water in a 
volumetric flask. 
Solution B: 0.05 M sodium tetraborate (MW 381.37 = 381.37 g/1000 mL): 
1.9069 g sodium tetraborate powder diluted to 100 mL with deionised 
water in a volumetric flask. 
 (v/v) Acetonitrile: Borate buffer (0.2 M, pH 8.9): 200 mL solution prepared by 
combining 100 mL acetonitrile + 100 mL borate buffer 
3.11 Simulation experiments 
3.11.1 Peripheral intravenous line 
For the peripheral IV line component, six gentamicin dose/flush volume conditions were 
proposed as described in Table 5: 
Table 5: PIV gentamicin dose/flush volume combinations 
2 mg dose 5 mg dose 
1 mL flush 1 mL flush 
2 mL flush 2 mL flush 
4 mL flush 4 mL flush 
 
Each was completed with six repetitions using the same intravenous line components, 
with a fresh set-up for each dose/volume combination. The order of testing was 
determined using a random number generator in Microsoft Excel 2013. Each component 
of the peripheral intravenous line was weighed, both empty and full of distilled water to 
allow calculation of the volume within the IV line. Numbered syringes with drug for 
administration and 0.9% saline flush were prepared. These were weighed empty, after 
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filling with the drug or flush solution and again after administration through the line to 
determine how much of the drug and flush was successfully administered. The line was 
flushed with 5 mL normal saline (and discarded) before each drug dose was administered 
and new components were used for each dose/flush volume combination. 
The model peripheral intravenous line was assembled on a flat workspace, with 
numbered plastic tubes to collect samples in as shown in Figures 3 and 4. 
 
Figure 3: Peripheral IV line simulation 
 
Figure 4: Components of PIV set-up 
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Gentamicin was administered by slow push over 2-3 minutes, followed by a saline flush 
over the same duration. Samples were stored in the freezer at -20°C until analysis by 
reverse-phase high performance liquid chromatography (HPLC).  
3.11.2 Umbilical Venous Catheter (UVC) 
For the UVC simulation series four dose/volume combinations were proposed as 
described in Table 6: 
Table 6: UVC gentamicin dose/flush volume combinations 
UVC Flow rate Gentamicin Dose Flush Volume 
0.5 mL/hr 2 mg 1 mL 
 2 mg 2 mL 
 5 mg 1 mL 
 5 mg 2 mL 
 
Each was completed with 6 repetitions, with the order of experiments determined using 
a random number generator in Microsoft Excel 2013. Each component of the line (UVC, 
smart site, filter, tubing) was weighed both empty and full of distilled water to allow 
calculation of the volume within the IV line. Numbered syringes with drug for 
administration and 0.9% sodium chloride flush were also prepared and were weighed 
empty, after filling with the drug or flush, and again after administration. New UVC 
components were used for each dose/flush volume combination experiment.  
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The model UVC was assembled on a flat workspace, with the carrier fluid pump 
containing 10% dextrose slightly raised on a pump stand as documented in Figures 5 and 
6. 
 
Figure 5: UVC simulation set-up 
 
Figure 6: Pump and UVC simulation 
Numbered plastic tubes in which to collect samples every 5 minutes for an hour after 
drug administration were prepared. Gentamicin was administered by slow push over 2-3 
minutes, followed by a saline flush over the same duration. A timer was set for 5 minute 
intervals and the end of each increment the catheter was moved to the next tube. The line 
was purged with 10% dextrose (and discarded) between each repetition. Samples were 
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stored in the freezer at -20°C until analysis by reverse-phase high pressure liquid 
chromatography.  
In order to ascertain how long the full dose of gentamicin took to give, one further 
experiment was done for each of the 4 gentamicin dose/flush volume combinations. This 
involved delivery of dose and flush as previously described, with a continuous 
background infusion rate of 0.5 mL/hr. Fluid was collected from the end of the UVC in 
half-hour increments for 2 hours and the line was purged with 10% dextrose through the 
pump after this and collected to be analysed.  
3.12 Analysis of samples 
Reverse-phase high pressure liquid chromatography (HPLC) analysis was conducted 
using a derivatisation reaction previously described and validated by Sherwin et al.2. 
Derivatisation was needed in order to add a fluorescent tag to the amine groups of the 
gentamicin molecule to allow it to be detected and depicted on a chromatograph.  
A separate standard curve of gentamicin sulphate stock solution (1 mg/mL) was prepared 
on each day of HPLC analysis in concentrations of 2 µg/mL, 5 µg/mL, 10 µg/mL, 20 
µg/mL, 50 µg/mL and 100 µg/mL in 10% dextrose. For the derivatisation reaction, 20 
µL of each gentamicin standard (or experimental sample after dilution) was added to 20 
µL of internal standard solution (tobramycin 0.5 µg/mL) and 980 µL of 
acetonitrile:borate buffer (v/v pH 8.9). 200 µL FMOC-Cl (2.5 mM in acetonitrile) was 
added after mixing and the samples were then mixed again and incubated at 30°C for 20 
minutes in a water bath. Following incubation, 50 µL of glycine (0.1 M) was added to 
stop the derivitisation reaction and samples were analysed in the HPLC instrument. 
The area under the C1a component peak of gentamicin which appeared on the 
chromatograph was measured and recorded as a ratio to the area under the tobramycin 
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internal standard peak. The concentration of gentamicin present in each sample was 
derived from the slope of the standard curve for each day. 
Quality control samples (at low, medium and high concentrations – 5 µg/mL, 40 µg/mL 
and 90 µg/mL respectively) were prepared and analysed each day also to ensure intraday 




4 Results: Neonatal nurses survey 
4.1 Overview: NICU nurses survey 
In order to clarify the actual routes and methods of intravenous gentamicin administration 
in Dunedin NICU a self-administered questionnaire was performed. This was done as a 
quality improvement exercise to document current nursing care practice. Thirty-seven 
out of forty-two nurses (88%) currently employed at Dunedin NICU returned the 
questionnaire. This study highlighted variations in clinical practice for gentamicin 
delivery within our unit which may impact on the pharmacokinetics of gentamicin in 
neonates. 
4.1.1 Site of gentamicin dose administration 
When asked about an extremely low birth weight 24-week gestation baby, 92% (34 
nurses) responded that they would administer a dose of gentamicin through the second 
lumen of the UVC which had a slower flow rate (0.5 mL/hr) compared to 8% who 
administered the drug through the primary lumen (2.1 mL/hr). In the second scenario the 
same drug (gentamicin) and options of site to administer were offered and in this case 
95% (35 nurses) answered that they would also administer the drug through the second 
lumen (flow rate 0.5 mL/hr vs 6.2 mL/hr through primary lumen). 
Free text answers were invited when the scenario was altered to include a peripheral 
intravenous line in addition to the double lumen UVC. The majority of responses 
indicated that the peripheral line would be used in preference to the UVC for gentamicin 
administration. The most common reason justifying this choice was to lessen the 




4.1.2 Flush volume to follow gentamicin dose 
Secondary information gained from this survey demonstrated that larger flush volumes 
were likely to be used when gentamicin was administered through the peripheral IV line 
and smaller flush volumes when it was given via the UVC as shown in Figure 7. In both 
scenarios the most premature, lowest birth weight neonate was likely to receive a smaller 
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As these data were collected in free-text format there were additional flush volumes that were 
also documented. In administering gentamicin via a peripheral IV line variable flush volumes 
were 0.5 mL before/1 mL after at 24 weeks gestation, and 0.5 mL before/2 mL after the 
gentamicin at 32 weeks gestation. Additionally, five ‘other’ volumes were described in the free 
text response box for PIV administration – four of “would discuss with medical team” and one 
“wouldn’t use PIV”. For the UVC, respondents replied that saline flushes of 1 mL before and 
after gentamicin, 0.5 mL before and after, and 0.5 mL before/1 mL after would be used at both 
gestations and in one case (in the 24-week gestation infant) the flush volume was unclear. 
Table 7 shows the average flush volumes used in each of the scenarios given in the survey. 
Despite the volume of the flush appearing smaller in the most premature baby, as percentages 
of total daily fluid intake (based on 90 mL/kg/day calculations) these flush volumes are greatest 
for the more premature baby. For example, when given via the PIV line, the flush volume of 
2.4 mL equates to 3.8% of the total fluid allowance for a 24 hour period in the 700 g 24-week 
gestation baby. The flush volumes estimated by NICU staff in this survey represent 1.9 – 3.8% 
of the 90 mL/kg/day fluid amount for the 24 week gestation baby and 0.9 – 2% of the total 
daily requirement in the 32 week gestation baby. 
Table 7: Average flush volumes given to neonates at different sites of administration 
Site of administration of 
gentamicin 
24-week gestation,  
700g 
32- week gestation,  
1800g 
Peripheral intravenous line 2.4 mL 3.2 mL 
Point A (secondary lumen, 
0.5mL/hr flow rate) 
1.35 mL 1.74 mL 
Point B (primary lumen, 
 90 mL/kg/day total fluids 
1.17 mL 1.42 mL 
4.1.3 Summary 
The findings of this study demonstrated that the slow-flowing, relatively free arm of the UVC 
was most commonly used to administer gentamicin when prescribed in extremely low birth 
weight premature neonates in Dunedin NICU. If a peripheral intravenous line was also 
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available this was frequently used in preference to the UVC due to nursing staff reluctance to 
compromise the sterile integrity of the central line. 
Flush volumes following the administration of gentamicin were smaller for the most premature 
baby but represented a greater proportion of total daily fluid intake in this group. 
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4 Results: Experimental work 
4.2 Overview 
The experimental work in Part B of this thesis builds on the background work from Part 
A in order to construct clinically-relevant simulation experiments for gentamicin 
administration to premature neonates. Two aspects of gentamicin administration are 
considered here – by peripheral IV line and through an umbilical central line – with 
different saline flush volumes used following antibiotic administration. 
4.2.1 Validation 
The gentamicin assay and HPLC method was validated with three separate runs on 
consecutive days by preparing quality control samples to detect precision and accuracy. 
Six quality control samples, at nominal concentrations of 5 µg/mL (low), 40 µg/mL 
(medium) and 90 µg/mL (high) of gentamicin sulphate in 10% dextrose were prepared 
fresh each day. Examples of standard curves generated in duplicate with 6 data points 
(intended concentrations of 2 µg/mL, 5 µg/mL, 10 µg/mL, 20 µg/mL, 50 µg/mL and 100 
µg/mL) are shown in Figure 8. The average retention time was 4.3 minutes for the internal 
standard and 11.3 minutes for the gentamicin C1a peak. This peak was used as the 
reference point in order to maintain consistency with previous studies2 41. Additionally, 
the change in retention time with three different concentrations of acetonitrile:water 







Figure 8: Examples of gentamicin sulphate standard curves prepared in 10% dextrose for analysis of (A) UVC 2 mg 
dose, 1 mL flush 3rd repetition (B) PIV 2 mg dose, 1 mL flush and (C) UVC 2 mg dose, 1 mL flush 4th and 5th 
repetition samples 
  


















Gentamicin sulphate concentration (µg/mL)



















Gentamicin sulphate concentration (µg/mL)




















Gentamicin sulphate concentration (µg/mL)
50 
 
4.2.2 Gentamicin assay 
Tables 8, 9 and 10 show results for the validation data at each of the nominal values of 
low, medium and high concentrations. The inter-day variability is consistently <15% but 
intra-day variability fluctuates from 0.37% to 21.29%, with the greatest variability 
observed on one replication at the lowest concentration. 
Table 8: Low (5 µg/mL) concentration validation data; concentration of gentamicin sulphate derived by day and 
replication attempt 
Replication 1 2 3 4 5 6 Mean SD %CV 
Day 1 4.61 5.74 4.51 4.12 4.76 5.1 4.81 0.56 11.61 
Day 2 4.48 4.94 4.95 5.88 5.38 4.67 5.05 0.51 10.06 
Day 3 4.06 4.3 4.78 4.16 4.34 4.03 4.28 0.28 6.44 
Mean 4.38 4.99 4.75 4.72 4.83 4.60    
SD 0.29 0.72 0.22 1.00 0.52 0.54    
%CV 6.56 14.45 4.67 21.29 10.84 11.70    
 
Table 9: Medium (40 µg/mL) concentration validation data; concentration of gentamicin sulphate derived by day 
and replication attempt 
Replication 1 2 3 4 5 6 Mean SD %CV 
Day 1 40.78 42.34 43.06 43.54 42.27 42.25 42.37 0.94 2.21 
Day 2 41.7 39.35 42.77 42.81 44.9 42.16 42.28 1.81 4.27 
Day 3 39.35 39.96 43.02 40.99 40.27 39.3 40.48 1.39 3.44 
Mean 42.77 40.55 42.95 42.45 42.48 41.24    
SD 1.18 1.58 0.16 1.31 2.32 1.68    
%CV 2.92 3.90 0.37 3.09 5.47 4.07    
 
 
Table 10: High (90 µg/mL) concentration validation data; concentration of gentamicin sulphate derived by day and 
replication attempt 
Replication 1 2 3 4 5 6 Mean SD %CV 
Day 1 92.55 95.47 94.71 98.23 102.39 89.12 95.41 4.58 4.80 
Day 2 90.7 92.23 101.28 92.95 92.12 93.57 93.81 3.78 4.03 
Day 3 85.65 91.2 83.91 88.27 89.75 91.16 88.32 3.00 3.40 
Mean 89.63 92.97 93.30 93.15 94.75 91.28    
SD 3.57 2.23 8.77 4.98 6.72 2.23    




4.2.4 HPLC gradient method 
The retention time for gentamicin sulphate shortened with increasing concentrations of 
acetonitrile (ACN) in the HPLC mobile phase as shown in the Figure 9. To ensure 
reproducibility on successive days of experiments a gradient system was used throughout 
this project. This was done in order to decrease the potential for error arising from 
inaccurate preparation of the mobile phase that may occur when using a premixed 
solution. 
 
Figure 9: Retention time vs concentration of acetonitrile in HPLC mobile phase for both internal standard (lower 
line) and gentamicin sulphate (upper line). 
Examples of the chromatogram generated by HPLC with fluorescence is shown in Figure 
10 at three different concentrations. On the left, the tobramycin (0.5 µg/mL) internal 
standard peak is visible and further to the right of the chromatogram the three components 
of gentamicin (C1a, C2 and C1 respectively) are visible as separate peaks in this order. 
The area under the C1a peak as a ratio to the area under the internal standard was used 
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Figure 10: HPLC chromatogram of tobramycin internal standard (0.5 µ/mL) on left and the 3 components of 
gentamicin sulphate in concentrations of (A) 5 µg/mL (B) 20 µg/mL and (C) 100 µg/mL on the right of the x axis. 
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4.3 PIV infusion studies 
Six experimental studies were completed during the peripheral IV line simulation series. 
As described in section 3.11.1 (Table 5), these consisted of combinations of two nominal 
gentamicin doses (2 mg and 5 mg) with three flush volumes (1 mL, 2 mL and 4 mL). 
Tables 11 and 12 illustrate the actual dose of gentamicin and flush volume that was 
administered in these experiments as measured by weight of the syringes. For the 2 mg 
series, the actual gentamicin dose administered is consistently greater than the nominal 
dose, by 0.1–1.3%, whereas in the 5 mg series the dose is less than 0.25% below the 
nominal dose. Flush volumes vary also, from -0.03% of the nominal volume to +1.73%. 
Table 11: Measured drug and flush volumes for six replications of each drug/flush combination in 2 mg PIV 
experimental series with flush volumes of 1 mL, 2 mL and 4 mL. 
 2 mg gentamicin dose PIV series 
 1 mL 2 mL 4 mL 
 Drug (mg) Flush (mL) Drug (mg) Flush (mL) Drug (mg) Flush (mL) 
1 2 1.02 2.06 2.01 2.02 3.99 
2 2.01 1.02 2 2.04 2.11 4.02 
3 2.02 1.02 2.04 2 1.98 4.04 
4 2.02 1.01 1.99 2.02 1.99 3.97 
5 2 1 1.96 1.97 2.04 3.94 
6 2.03 1.03 1.96 2.04 2.02 4.03 
Mean 2.01 mg 1.02 mL 2 mg 2.01 mL 2.03 mg 4 mL 
SD 0.01 0.01 0.04 0.03 0.05 0.04 
 
Table 12: Measured drug and flush volumes for six replications of each drug/flush combination in 5 mg PIV 
experimental series with flush volumes of 1 mL, 2 mL and 4 mL. 
 5 mg PIV series 
 1 mL 2 mL 4 mL 
 Drug (mg) Flush (mL) Drug (mg) Flush (mL) Drug (mg) Flush (mL) 
1 5.04 1.02 4.93 2.01 4.86 4.03 
2 5.04 1.01 5.06 2.01 5.33 4.02 
3 4.95 1 5.02 2 4.88 3.99 
4 5 1.02 4.95 2.01 4.9 3.99 
5 5.05 0.99 5.01 1.99 5.05 3.99 
6 4.86 1.04 5.02 2.04 4.95 4.01 
Mean 4.99 mg 1.01 mL 5 mg 2.01 mL 5 mg 4.01 mL 




Figure 11 displays the amount of gentamicin recovered (and standard deviation) from the 
end of the peripheral IV line after gentamicin doses of 2 mg and 5mg were administered, 
followed by 1 mL, 2 mL or 4 mL flushes of normal saline. The gentamicin dose was 
given as 0.2 mL or 0.5 mL of a 10 mg/mL solution, and the mean internal volume of the 
PIV tubing (cannula, extension, smart site and filter) was 1.19 mL. The dotted line 
indicates the mean intended dose. These results indicated that a 4 mL flush was required 
to recover all of the 2 mg dose administered into a peripheral IV line, whereas a 2 mL or 
greater flush was required in order to ensure complete recovery of the 5 mg administered 
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Figure 11: Recovery of gentamicin after administration via a peripheral intravenous line with flush volumes of 1 mL, 2 mL and 4 mL. (A) 2 mg gentamicin dose administered; (B) 5 mg 




4.4 UVC infusion studies 
4.4.1 One hour infusions 
Fluid discharged from the end of the UVC infusion was collected at 5 minute intervals 
for an hour following each dose/flush volume combination experiment and will each be 
discussed in turn. The mean volume of dead space of the IV line tubing from the point of 
drug administration to the patient end of the line (UVC 20 guage primary lumen, smart 
site and filter) was 1 mL. Experiments were repeated 6 times and standard deviations are 
shown on each figure. 
4.4.1.1 2 mg dose 
In the experiments where a 2 mg dose was intended, Table 13 shows the actual amount 
of drug and flush administered in each replication based on the weight of the syringes. 
The gentamicin preparation used clinically and in these experiments is 10 mg/mL, 
therefore 0.2 mL was required for administration in this series. As the result of variable 
measurements, on average a 3.9% greater dose was administered in the 2 mg/1 mL series 
and 6.3% greater dose in the 2 mg/2 mL series. The actual volume of flush administered 




Table 13: Measurements of drug and flush administered for 2 mg experimental series 
Intended drug & flush volume 
Experiment number 
2 mg dose, 1 mL flush 2 mg dose, 2 mL flush 
Drug dose                                   1. 2.29 2.02 
(mg)                                            2. 2.08 2.06 
3. 2 2.23 
4. 2 2.2 
5. 2.03 2.06 
6. 2.03 2.2 
Mean 
SD 




Flush volume                             1. 1 1.98 
(mL)                                            2. 1.01 2.01 
3. 1.01 2.01 
4. 0.98 1.95 
5. 0.97 1.96 








Fluid expelled from the end of the UVC tubing was collected at 5 minute intervals (timed 
from t=0, the start of drug administration) and analysed for gentamicin content by HPLC. 
Table 14 shows the cumulative amount of gentamicin recovered at each of these intervals 
for the 6 repetitions of each flush volume in combination with a 2 mg administered dose. 
Differences in the amount recovered as compared with the intended dose may be partly 
explained due to the administration of pharmaceutical-grade gentamicin as compared 
with the dry powdered stock solution that was used for to prepare the standard curves. 
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Table 14: Cumulative amount of gentamicin recovered during each 5 minute interval for one hour following 2 mg nominal dose administration 





 5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 50 min 55 min 60 min 
2 mg 1 mL 1 1.73 1.81 1.85 1.89 1.92 1.95 1.98 2.03 2.05 2.07 2.09 2.1 
2 1.54 1.83 1.86 1.92 1.95 1.98 2.0 2.03 2.05 2.07 2.08 2.1 
3 1.29 1.55 1.58 1.62 1.65 1.68 1.71 1.74 1.76 1.79 1.80 1.83 
4 0.66 1.80 1.88 1.94 2.00 2.06 2.09 2.14 1.18 2.02 2.23 2.25 
5 1.6 1.86 1.91 1.95 1.99 2.02 2.05 2.08 2.11 2.12 2.14 2.15 
6 0 2.14 2.20 2.26 2.64 2.31 2.35 2.39 2.42 2.44 2.46 2.47 
2 mL 1 0.41 1.49 1.49 1.50 1.50 1.50 1.50 1.50 1.51 1.51 1.51 1.51 
2 1.89 2.06 2.07 2.07 2.08 2.08 2.08 2.09 2.09 2.10 2.10 2.11 
3 1.97 2.10 2.10 2.10 2.10 2.11 2.11 2.11 2.11 2.11 2.12 2.12 
4 1.70 1.99 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
5 1.57 1.85 1.86 1.86 1.86 1.86 1.86 1.87 1.87 1.87 1.87 1.88 




For a 2 mg dose (0.2 mL of 10 mg/mL solution) Figure 12 illustrates that the amount of 
gentamicin recovered rises dramatically with both a 1 mL flush and a 2 mL flush from 
time=0. There was a gradual increase in the gentamicin successfully recovered from the 
end of the UVC over the course of an hour when a 2 mg dose was given followed by a 1 
mL flush. After one hour, all of the 2.08 mg measured dose (calculated based on weight 
of syringes) had been recovered when gentamicin was followed by a 1 mL flush. When 
a 2 mL flush was used 92% of the dose (1.88 mg out of 2.13 mg calculated by weight) 






Figure 12: Cumulative gentamicin recovery and percentage of intended dose recovered following administration of 2mg gentamicin (0.2 mL of 10 mg/mL solution) via a UVC with a consistent 




Figure 13 shows the administered dose recovered over time during the one hour UVC 
infusion. Of the 2.15 mg administerd dose recovered when a 1 mL flush was used, 85% 
of this was recovered by 10 minutes and 93% in the first 30 minutes. In comparison, 
when a 2 mL flush was used 99% of the 1.88 mg administered dose was recovered within 
the first 10 minutes. The greatest variability was seen in the first 5 minutes for both flush 
volumes, with standard deviations of 21.07% and 40.72% in the 1 mL and 2 mL flush 
volume series respectively. This variability was much smaller after 10 minutes had 
elapsed, with standard deviations of between 0.09% and 3.1%. 
 
Figure 13: Recovery of 2 mg administered gentamicin dose over 1 hour infusion duration when followed by 1 mL 
and 2 mL flush volumes. Mean and SD of 6 replications for each flush volume. 
4.4.1.2 5 mg dose 
In the experiments where a 5 mg dose was intended, Table 15 shows the actual amount 
of drug and flush administered in each replication based on the weight of syringes. These 
experiments required 0.5 mL of the 10 mg/mL gentamicin solution to be administered 
and there was variability in the dose administered even though the same investigator 
prepared every syringe for both the drug and flush. In the series with a 1 mL flush, the 
gentamicin dose was 4.5% greater than intended, whereas in the series with a 2 mL flush 
only a 1.4% measurement error was observed. As seen in the 2 mg experiments, the 
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volume of flush was closer to the nominal volume in this 5 mg experimental series as 
well. 
Table 15: Measurements of drug and flush administered for 5 mg experimental series  
Intended drug & flush volume 
Experiment number 
5 mg dose, 1 mL flush 5 mg dose, 2 mL flush 
Drug dose                                1. 5.01 5.03 
(mg)                                          2. 5.2 5.14 
3. 5.81 5 
4. 5.42 5.01 
5. 5.01 5.21 
6. 4.93 5.03 
Mean 
SD 




Flush volume                          1. 1 1.96 
(mL)                                         2. 1 2 
3. 1.02 2.01 
4. 1.01 1.99 
5. 1 1.96 








As with the 2 mg experimental series, fluid expelled from the end of the UVC tubing was 
collected at 5 minute intervals and analysed for gentamicin content by HPLC. Six 
repetitions of each dose/volume combination were completed, but replication 1 of the 5 
mg dose/2 mL flush combination was excluded from the analysis due to pump 
malfunction. Table 16 shows the cumulative amount of gentamicin recovered at each of 
these intervals for following 5 mg dose administration. 
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Table 16: Cumulative amount of gentamicin recovered during each 5 minute interval for one hour following 5mg nominal dose administration 





 5 min 10 min 15 min 20 min 25 min 30 min 35 min 40 min 45 min 50 min 55 min 60 min 
5 mg 1 mL 1 0 4.13 4.15 4.23 4.32 4.41 4.49 4.53 4.59 4.63 4.67 4.70 
2 4.29 5.30 5.39 5.46 5.54 5.60 5.68 5.73 5.77 5.82 5.84 5.85 
3 1.43 4.36 4.42 4.48 4.53 4.57 4.61 4.64 4.67 4.69 4.70 4.72 
4 3.29 5.74 5.79 5.83 5.87 5.89 5.92 5.94 5.95 5.97 5.97 5.98 
5 4.74 5.89 5.93 5.97 6.00 6.02 6.04 6.06 6.07 6.08 6.09 6.10 
6 2.56 5.67 5.72 5.79 5.86 5.92 5.96 5.99 6.00 6.02 6.03 6.04 
2 mL 1 Excluded due to pump failure 
2 3.70 4.39 4.41 4.42 4.43 4.44 4.45 4.45 4.46 4.47 4.47 4.49 
3 4.28 5.41 5.42 5.42 5.43 5.43 5.44 5.45 5.45 5.45 5.46 5.46 
4 0.96 5.48 5.49 5.49 5.50 5.50 5.51 5.51 5.51 5.51 5.52 5.52 
 5 4.59 6.01 6.01 6.02 6.02 6.02 6.02 6.02 6.03 6.03 6.03 6.04 




For a 5 mg dose (0.5 mL of 10 mg/mL solution given over 3-5 minutes, followed by a 
flush over the same duration) Figure 14 shows that the amount of gentamicin recovered 
rises dramatically with both a 1 mL flush and a 2 mL flush from time 0. When the 5 mg 






Figure 14: Cumulative gentamicin recovery and percentage of intended dose recovered following administration of 5 mg gentamicin (0.5 mL of 10 mg/mL solution) via a UVC with a consistent 




Figure 15 shows the administered dose over the course of the hour-long infusion. When 
a 1 mL flush was administered following the 5 mg (0.5 mL) dose of gentamicin, 93% of 
the total 5.56 mg was recovered in the first 10 minutes, and 97% in the first 30 minutes. 
With a 2 mL flush, 99% of the 5.6 mg administered dose was recovered at 10 minutes. 
As seen in the 2 mg gentamicin dose series, the greatest variability in percentage of 
administered dose recovered was evident in the first 5 minutes. In this 5mg series, the 
standard deviation of samples at 5 minutes was 28.99% with a 1 mL flush and 27.83% 
with a 2 mL flush, but after 10 minutes this standard deviation was between 0.09% and 
3.36% across both simulations. 
 
Figure 15: Recovery of 5 mg administered gentamicin dose over 1 hour infusion duration when followed by 1 mL 
and 2 mL flush volumes. Mean and SD for 6 replications of 1 mL flush and 5 replications of 2 mL flush experimental 
series. 
4.4.2 Two hour infusions 
In order to determine how long the total amount of gentamicin took to be recovered from 
the end of the UVC, one further experiment was completed in which each dose/volume 
combination was administered separately and samples collected at half-hour intervals for 
2 hours. This was followed by a large bolus of dextrose through the IV line to ensure all 
of the drug was flushed through and could be recovered. This showed that 87% of a 2 mg 
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dose (followed by a 1 mL flush) was recovered within 30 minutes and 93% by the end 
of 1 hour, whereas 95–97% of the other doses were recovered within 30 minutes when 
each is accompanied by a stable carrier fluid flow rate of 0.5 mL/hr. Each dose/flush 
volume combination is shown in Figure 16 with the dotted horizontal lines indicating the 




Table 17: Cumulative amount of gentamicin recovered during each 30 minute interval for two hours following administration with large flush at 150 minutes 
Flow rate Dose Flush volume Cumulative amount of gentamicin recovered during each 30 minute interval (mg) 
30 min 60 min 90 min 120 min 150 min 
0.5 mL/hr 2 mg 1 mL 2.11 2.25 2.33 2.36 2.41 
 2 mL 1.91 1.93 1.95 1.95 1.95 
 5 mg 1 mL 4.69 4.85 4.92 4.94 4.94 
 2 mL 5.38 5.42 5.49 5.51 5.54 
 
 
Figure 16: Cumulative gentamicin recovery over 2 hours after bolus dose administration of 5 mg or 2 mg followed by 1 mL and 2 mL flush volumes. Dotted line indicates mean intended dose 
for each dose/volume experimental combination 
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4.5 Dye experiments 
Retrograde flow up the intravenous line (leading away from the patient) was observed 
when dye was used to mimic the drug administration phase during one replication of each 
dose/flush volume combination as shown in the series of photographs in Figures 17 and 
18. These illustrate dye flowing up the line when it was first administered and then 
clearing at different speeds depending on the volume of flush that follows it. When a 2 
mL flush was instilled, the line below the port was clear of drug before the syringe was 
detached, but dye remained in the tubing above this point. The port was then seen to 
back-fill with dye as the flush-containing syringe was detached, and then the remainder 
of the line was cleared by the carrier flow. When a 1 mL flush was instilled, a slower 
clearing of the line below the drug injection site was observed in addition to dye 























       
Figure 17: Injection of 0.2 mL 1% (w/v) congo red dye followed by (A) 1 mL flush and (B) 2 mL flush. Photos at intervals of (i) end of dye administration, (ii) beginning and (iii) end of flush 















   
Figure 18: Injection of 0.5 mL 1% (w/v) congo red dye followed by (A) 1 mL flush and (B) 2 mL flush. Photos at intervals of (i) end of dye administration, (ii) beginning and (iii) end of flush 





The findings of Part B, the experimental phase of this thesis, have focused on 
investigating the impact that two different flush volumes have on the amount of 
gentamicin recovered after administration of two different doses by peripheral IV line 
and umbilical central line. The experimental conditions for these simulations have been 
based on conditions which are used in the Dunedin hospital NICU so as to make the 
results of this experiment applicable and clinically relevant to premature babies receiving 
intensive care. 
The first set of results from this experimental work showed that a flush volume that was 
at least as large as the internal volume of the peripheral IV line was required for the full 
dose of gentamicin to be recovered after administration. This was especially noticeable 
with the smaller dose as it was administered in a correspondingly small volume of fluid. 
The second set of results from this part confirmed that >80% of both 2 mg and 5 mg 
doses of gentamicin given via a UVC was able to be recovered from the end of the line 
10 minutes after it was administered as a bolus when followed by a flush of either 1 mL 
or 2 mL of normal saline. The percentage of gentamicin recovered was lowest for a 2 mg 
dose with a 2 mL flush under these experimental conditions, where the flow of the carrier 
fluid (10% dextrose) remained constant at 0.5 mL/hr. Retrograde flow of dye was noted 






The survey and the subsequent laboratory investigations completed for this thesis suggest 
that to increase successful gentamicin dose recovery in the NICU greater consideration 
should be given to the methods of drug and flush administration. Variability has been 
illustrated in the site of administration, volume of drug and flush volume prepared and in 
the infusion itself over time. Issues such as individual measurement techniques, dead 
space volume of the intravenous line components and retrograde flow all contribute to 
successful recovery of gentamicin and may consequently affect treatment of early-onset 
sepsis in NICU babies. 
5.2 Variability in current clinical practice 
The significant findings revealed as part of the NICU nurses survey were: 
 That the 2nd lumen of a UVC was favoured by nurses in Dunedin NICU to 
administer a dose of gentamicin to a premature baby, but that a PIV line would 
be used preferentially if this was available. 
 A wide variation in flush volume occurred in Dunedin NICU when gentamicin is 
administered by both UVC and PIV methods. 
 The most common reason for using a PIV in preference to a UVC, amongst NICU 
nurses, was to reduce the infection risk to the baby by preserving the sterile 
integrity of the TPN line. 
These contemporary findings will be discussed in turn in the following paragraphs and 
contextualised. There has not been a direct comparison between different methods of 
gentamicin administration or of nursing preference for different routes of administration 
published in the literature.  
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One survey of a similar nature, completed by neonatal and paediatric nurses regarding 
gentamicin delivery, also displays a large amount of variation in the preferred site of 
administration and 75% of these respondents varied their site of administration 
depending on the flow rate of the infusion66. The variation described in the current survey 
reveals differences in nursing practice across the unit, and may also represent 
modifications to the care of the same baby in different shifts over the course of the day. 
This could result in fluctuating systemic levels of gentamicin which might be clinically 
significant over the course of their sepsis event. The pharmacokinetics of gentamicin are 
anticipated to differ depending on where and how the drug is administered as this impacts 
on the time it takes for the drug to reach the circulation as discussed in section 1.3.1. As 
there are often long lengths of tubing used in the intravenous line architecture for preterm 
babies the delivery of the drug is unpredictable. It has been observed that the time from 
administration to the drug appearing at the patient-end of an infusion can be predicted 
based on the flow of the line and the dead space volume of the tubing, but the actual time 
taken for the infusion to be completed is longer than would be expected based on these 
calculations66. This is a particularly important feature to be aware of when changes to the 
drug dose or interval are required based on serum measurements, as occurs with 
gentamicin, as these decisions may be based on the incorrect assumption that the whole 
of a dose has been delivered within a specified time period. 
A flush is instilled following a dose of medication given intravenously in order to ensure 
that the drug is cleared out of the infusion system, though there are no studies with 
recommendations of minimum flush volume required for different infusion 
configurations29. Previously it has been shown that administration of a 2 mL saline flush 
following a dose of gentamicin administered by continuous infusion improved the 
amount of drug recovered by 19% in extremely low birth weight neonates2. The flush 
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volume that is administered needs to be considered in the context of the total fluid 
requirements of the baby over a 24 hour period, especially if medications are 
administered multiple times each day or if numerous medications are prescribed 
concurrently, in order to prevent fluid overload. In the NICU survey completed here it 
was indicated that the flush volumes used following the administration of gentamicin 
would be smaller for the most premature baby, but these represented a greater proportion 
of the total daily fluid intake in this group. The potential implication for medications 
given multiple times per day and for babies receiving numerous medicines is that babies 
would be receiving 0.9% saline as a flush at the expense of nutrition-containing fluids.  
Parenteral nutrition solutions are commonly prepared under sterile conditions in the 
hospital pharmacy prior to their use in the NICU. To maintain the sterility of the fluid, 
extended lines which require changing every 48 – 96 hours are attached to existing 
intravenous devices, though the optimal timing for making these changes taking into 
account colonisation, infection, mortality and nursing time is not definitively 
understood67. Within the intravenous line configuration it has become routine practice to 
include an in-line filter (such as the Pall ELD96) in order to prevent contamination and 
microemboli from microparticles that may be found in nutrition or medication solutions68 
69. However, medications such as gentamicin can be administered downstream of this 
endotoxin-retentive filter (above a 0.2 micron air-eliminating filter only), which could 
result in bacterial contamination of the sterile line. Of greater concern is the potential for 
proliferation of bacteria once they are introduced, because of the nutritional components 
of the fluid, which could then result in iatrogenic bacteraemia and neonatal sepsis70 71. 
This concern is felt to relate primarily to the lipid emulsion component, though a 1998 
prospective study exposing samples of TPN fluid to 12 nosocomial pathogens resulted in 
growth of only C. albicans and S. saprophyticus at 24 – 48 hours, concluding that total 
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nutrient admixture was a poor growth medium for most nosocomial infections and no 
better than 5% dextrose72. 
In a paediatric ICU setting, there was an increased risk of bloodstream infection seen 
with receipt of parenteral nutrition (OR 3.12) and with UVC placement in particular73 74. 
However no significant difference was found in the systemic infection rates when 
comparing TPN delivered by PICC line versus PIV line in a Cochrane review75. The 
concerns raised by nursing staff in this Dunedin survey regarding iatrogenic 
complications related to parenteral nutrition are echoed in the literature76 77 and should 
be considered when writing drug protocols for infants who require parenteral nutrition. 
5.3 Peripheral line infusion variables  
The main finding from the PIV experimental series was: 
 A flush that is at least as large as the internal volume of the line is required in 
order to deliver all of the intended dose when gentamicin is administered by a 
peripheral IV line.  
The flush volume required following drug administration by PIV line has not been 
definitively established in the scientific literature. This may be because different 
configurations of intravenous line components are used in different hospitals but it is an 
important pharmacokinetic parameter to consider. 
The internal volume of the intravenous line architecture needs to be taken into 
consideration when administering medications by bolus injection or continuous infusion 
as well as at different sites along the line. Neonatal lines have been designed to minimise 
the dead space within them by methods such as low-volume tubing though there are likely 
to be different configurations used in different hospitals29. As well as minimising the 
internal volumes, low-volume tubing decreases the risk of fluid layering occuring29. In 
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the current study, average measured dead space from the port where the drug was 
administered to the patient end of each line was 1.19 mL for the PIV experiments (range 
1.12 – 1.29 mL) and 1 mL for the UVC series (range 0.96 – 1.02 mL). While these 
measurements are similar to the reported capacity measurements on the packaging, 
relying exclusively on these may underestimate the interal volume, as that of the Smart 
Site was not published and some variability in capacity of each individual component 
may exist. Given the small internal IV line volume, it could be expected that complete 
recovery of both 2 mg (0.2 mL) and 5 mg (0.5 mL) doses of gentamicin would occur 
after a 2 mL flush as this would completely displace the volume of the line. However, 
although this was found to be true for the larger 5 mg dose, it was not so for the smaller 
2 mg dose. It is possible that the smaller dose requires a larger flush for complete recovery 
because it is dispersed along the length of the tubing more in keeping with a “well-mixed” 
drug delivery model than the proposed alternative “plug-flow” model78. It is also possible 
that some of the drug remained adhered to components of the line such as the filter, thus 
making it unrecoverable. Previous experiments have shown gentamicin recovery to be 
complete when a 2 mg (0.2 mL of 10 mg/mL solution) dose was infused through a 
Poisyne Neo filter with a background carrier flow rate of 3.8 mL/hr30, but have not 
investigated the Safti-ject SV® filter which was used in these experiments. 
5.4 Central line infusion variables 
The most notable findings from the UVC experimental series were:  
 Retrograde flow of dye away from the patient was noted under all conditions. 
 A larger flush (2 mL) resulted in faster recovery of the administered gentamicin 
dose than a small flush (1 mL). 
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 When gentamicin was administered into the slow-flowing second lumen of a 
UVC by bolus injection it appeared to be recovered as well as previous studies 
where the dose has been administered into a faster flowing primary line. 
The dye model experiments help to explain some of the findings for the UVC series. 
With a larger flush, the line below the port is completely clear of drug before the syringe 
is detached, leaving only a small amount of drug above the port to be cleared by the 
carrier flow whereas with a smaller flush volume, dye remains above and below the port 
after the flush is completed, and requires the carrier flow rate to deliver a visibly greater 
proportion of the dose. Additionally, some of the dye that remained above the port after 
the flush was completed was seen to back-fill the port itself when the empty syringe was 
removed, and thus was not cleared by the carrier fluid. The proportion of dye remaining 
in the hub is likely to be more significant when a smaller dose is intended, but this has 
not been formally quantified in these experiments. This may help to explain why there is 
a discrepancy between the intended dose and recovered dose for the 2 mg/2 mL series, 
where less was recovered than was intended to be administered, and may also contribute 
to the apparent increased recovery of drug dose with subsequent replications of the same 
flush/volume combination as the port is primed with additional drug volume in these 
experiments. This observation is consistent with the work of Lovich et al.78. Although 
this apparent loss of drug is not seen in the 2 mg/1 mL series when gentamicin recovery 
was measured, only one replication of the dye experiment was completed for each 
dose/volume combination, and it is to be expected that a degree of variation would exist 
in these experiments as was seen in the gentamicin recovery experiments. Previous 
studies have also investigated retrograde flow of dye in various configurations of 
neonatal IV line giving sets and it has been observed that retrograde flow was more 
pronounced in infusions with a flow rate of 2 mL/hr whereas it was not seen in infusions 
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at 10 mL/hr41, and was more notable when the primary infusion fluid was of a different 
specific gravity from the solution being instilled or when the T-connector was angled 
upwards by 15°30. At an even slower rate, as was used in these experiments, the 
retrograde flow effect could become even more pronounced. 
Previous simulation experiments have shown a correlation between slow carrier flow 
rates with small drug doses and poor recovery of the administered dose from the end of 
a peripheral intravenous catheter when the dose and flush are given as continuous 
infusions2. In this study, at a slower carrier flow rate, it has been shown that this recovery 
can be improved by administering the gentamicin dose as a bolus. This is consistent with 
other work using the same doses (2 mg and 5 mg) at higher flow rates (2 mL/hr and 10 
mL/hr)41 and additionally with larger drug doses30. However, in contrast, earlier work 
showed that the longest drug infusion time occurred with slow IV flow rates in 
combination with large dose volumes79. In addition to carrier fluid rate, the site of 
injection and volume of drug to be injected also significantly influence the length of 
infusion time80. The rapidity of recovery is greatest in the current study when a larger 
flush volume (2 mL in comparison to 1 mL), is used but there is a large degree of variation 
in the amount of gentamicin recovered within the first 5 minutes in all of the dose/flush 
volume combinations. Beyond 10 minutes there was only a small amount of drug 
expelled at each five minute interval (<1% of the intended dose), which became difficult 
to detect with the current assay, but this method could be optimised for future research. 
Although neonatal infusion configurations have evolved to enable drugs and nutrition-
containing fluid to be connected together and run simultaneously, the ideal system which 
enables independent delivery of each is not yet known69 80. Interventions such as anti-
reflux valves and very low volume deadspace may contribute to more consistent and 
timely drug administration in the NICU. 
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5.5 Measurement variability  
One further observation that can be made from this experimental work is: 
 That variability in measured drug and flush volumes for administration was 
identified and was more pronounced with smaller volumes of fluid. 
In this work, inter-individual variability was not quantified because one investigator 
prepared all of the syringes of drug and flush for administration. However, there was 
considerable intra-individual variability, even under controlled conditions in a 
laboratory, with up to a 6.3% greater than intended dose administered (in the 2 mg drug/2 
mL flush UVC series). This variability is likely to increase in situations of high workload 
and stress in the intensive care environment and is particularly concerning because a 
number of drugs requiring small volumes of fluid are used in the NICU. These findings 
support previous research illustrating the greater variability in drug doses prepared in the 
NICU as compared to those prepared in pharmacy settings35 and when doses requiring 
dilution are needed36. Previous simulation experimental work by Godden in Dunedin41 
also confirms the inconsistency between the actual and intended doses of gentamicin. In 
that study it was felt that as the administered drug doses were consistently lower than 
intended (-7.78% for the 2 mg dose and -5.2% for the 5 mg dose) this may have 
contributed to the low dose recovery seen in the infusions with a slower background flow 
rate41. This is not likely to be the case in the present work however, as all of the intended 
doses were recovered for 3 of the 4 experimental dose/volume combinations. In the series 
where less than the intended dose was delivered (2 mg dose/ 2 mL flush volume), it is 
possible that serial or inaccurate dilutions contributed to the low recovery seen. The 
inconsistency in drug dose administered may contribute to errors in serum drug level 
interpretation which could result in changes being made to drug doses or dosing interval 
that have the potential to result in clinically significant adverse effects (due to drug 
81 
 
accumulation resulting in nephrotoxicity or ototoxicity), or to potentiate treatment failure 
for septic premature infants. Although there might not be ways to eliminate the risk of 
inconsistent drug dosing completely as these are subject to human error, it may be 
possible to mitigate the effect that these have by raising awareness of the problem and 
encouraging further research, particularly in the area of neonatal pharmacology where 
small volumes are routinely required. 
5.6 Strengths and weaknesses 
The NICU nurses survey is limited by several factors, in particular that it contains 
information from one tertiary NICU only and as such may not be generalisable to other 
units. During the completion of the questionnaire nurses were permitted to read the unit 
drug administration manual and to discuss the questions amongst themselves. Although 
this has the potential to create bias it reflected routine practice and emphasis was placed 
on what would actually be done, not what was recommended in the protocol. A 
significant strength of the survey is the excellent response rate from nursing staff. 
The laboratory work is limited by its nature as a simulation in a controlled environment 
and as such may not reflect true physiological processes. Additionally there were no 
measurements done on peak or trough concentrations – it is assumed that the gentamicin 
administered remains physiologically active but this may actually be being excreted 
before the peak serum level is obtained in routine clinical practice since the drug enters 
the patient’s circulation over an extended period of time. The strengths of this 
experimental work are that there were many repetitions done and that one investigator 
did all the drug/flush measurements during the experiment and dilutions in the HPLC 
analysis. Both of these factors ensure the consistency of the results, so the variability that 
is noted can be attributed to the infusion itself rather than an individual. The experiments 
use current clinical practice as the basis for the simulation in that the components of the 
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line and syringes used for administration of the drug and flush are the same as those used 
in Dunedin NICU. This ensures that the results are able to be generalised from the 
laboratory to this clinical setting. 
5.7 Summary 
This body of work has demonstrated several findings relevant to clinical practice in the 
NICU. Firstly, that there is variability in the way that gentamicin is currently given in the 
clinical setting, which may differ from the way that researchers and clinicians assume 
that it is given (and in the way that doctors interpreting gentamicin levels also imagine 
that it is given). A common concern in the care of premature neonates is maintaining the 
sterility of the UVC lumen dedicated to parenteral nutrition fluid which can affect the 
choice of location to administer a dose of gentamicin. Secondly, it is possible to reveal 
that a flush of 4 mL is required to ensure complete delivery of a 2 mg dose through a 
peripheral IV line with the current configuration used in Dunedin NICU, whereas a flush 
of 2 mL only is required when it follows a dose of 5 mg administered peripherally. The 
reasons for this discrepancy in required flush volume are not fully understood. Thirdly, 
there is a degree of variation in the measured volumes in syringes that are used for drug 
and flush administration. The clinical significance of this is difficult to quantify, but this 
variation may contribute to the differences observed in serum levels that is noted when 
peak and trough measurements are taken, which in turn has implications for the 
interpretation of these results and subsequent dose adjustments to prevent adverse events 
occurring. Fourthly, with regard to UVC administration, this work has demonstrated that 
when a dose of gentamicin is given into the 2nd lumen of a UVC it is successfully 
administered faster when followed by a larger flush than a smaller one. This is notable 
because the 2nd lumen typically has a slower carrier fluid rate than the primary 
(parenteral-nutrition-containing) line and although the dose is recovered slower with a 
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smaller flush it does not seem to take dramatically longer. The implications of this are 
that doses can be recommended to be given as a bolus injection (as opposed to previously 
when continuous infusion of dose and flush over 30 minutes were advised) and recovery 
of 90% of the administered gentamicin dose can be anticipated within 30 minutes 
regardless of the flush volume that is used. Retrograde flow and back-filling of the port 
used for UVC gentamicin administration was noted in these experiments and may be 
under-appreciated in the clinical NICU setting.  
It is not possible to say from this research, however: 
 When the optimal time for measuring a peak concentration would be. 
 Whether the peak levels attained would be in the therapeutic range. 
 What the optimal dose is for premature neonates in order to achieve therapeutic 
peak concentrations. 
 The ideal method of administering gentamicin so that retrograde flow does not 
occur at slow carrier flow rates. 
5.8 Implications for further research 
It was beyond the scope of this research project to develop a model to predict the 
appropriate time for measuring peak serum concentrations of gentamicin in premature 
babies. The hope is that the data collected here will be able to be pooled with previous 
studies in order to create this model and ultimately to complete these simulations. These 
data may be able to support recommendations for the flush volume to be administered 
(peripherally and centrally) based on the recovery of gentamicin observed. Furthermore, 
as this was a laboratory-based project there are numerous clinical factors which have not 
yet been considered. Physiologically, the volume of fluid the baby receives is an 
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important consideration as is the volume of blood required for testing of serum 
gentamicin levels and the clinical condition of the baby. These factors and their 




Variability in neonatal gentamicin infusions is illustrated in a number of different ways 
in these experiments. This has added to current understanding about the influence of 
background infusion rate and flush volume on recovery of gentamicin when prescribed 
in the NICU setting.  
Our survey of current neonatal nursing practice for administration of gentamicin in the 
48 hours immediately after birth showed variability in the site of drug administration and 
the flush volume that would be used. Free-text responses indicated that the most common 
reason for administering a dose of gentamicin through a PIV line if this was available 
was to preserve the sterile integrity of the umbilical central line. 
The survey data was used to formulate experimental studies investigating the recovery 
of gentamicin when administered in different venous access devices. In order to fully 
recover a dose of gentamicin when it is administered via a PIV line, the flush volume 
must be greater than the dead-space of the IV infusion components through which it is 
being administered. With the current set-up in Dunedin NICU used in this experiment, 
the smallest flush volume that allowed full dose recovery of both 2 mg and 5 mg 
gentamicin doses was 4 mL. 
However, when administered via the UVC with a consistent slow background infusion 
rate of 0.5 mL/hr recovery of the intended gentamicin dose of 2 mg or 5 mg is observed 
when both 1 and 2 mL flush volumes used. There is considerable variability in the amount 
of drug recovered at 5 and 10 minutes but less inconsistency in all cases after 10 minutes 
have elapsed and > 90% dose recovery by 1 hour.  
Variability is also noted in the volumes of drug and flush prepared for administration 
which could have clinically significant effects on the treatment of neonatal sepsis. 
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Retrograde flow of dye was noted which may explain some of the variability seen in 
gentamicin recovery. These findings support the clinical practice of measuring peak 
serum gentamicin levels 30 – 60 minutes after administration of gentamicin via UVC 
into a slow-flowing background infusion but this recommendation does not take into 
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8.1 Dunedin Hospital gentamicin dosing protocol 
Gentamicin Sulphate - NICU Medication Manual 
(Otago) 
Note: All medication must be checked by two registered practitioners prior to 
administration. 
Aminoglycoside antibiotic 
Route Dosage Preparation 
Slow IV push over 3-5 minutes 
[Dose volumes less than 1mL 
(10mg) can be given as a fast 
push. The first 1mL of any dose 
can also be given as a fast push.] 
IM injection is associated with 
variable absorption, especially in 
the very small infant 
See dose chart below Injection (ampoule) 
10mg/1mL (solution) 


















level at 24 
hours: 
See below 




>35 ALL 4 
Use Treatment of infections caused by aerobic gram-negative bacilli 
(e.g. Pseudomonas, Klebsiella, E.coli). Usually used in 
combination with a ß-lactam antibiotic (e.g. amoxicillin). 
Monitoring  Monitor peak and trough levels with the 1st dose 
and again after the 3rd dose  
 Monitor renal function (urea and creatinine).  
 Peak levels should be measured 1 hour after 
administration.  
 Trough levels should be measured 23 hours 
after administration.  
 Trough - < 2 microg/mL  
 When the interval is extended >24hrs 
there is no need to take another trough before 
giving the dose in most cases.  
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 Peak - 6-12 microg/mL 
 If the peak is too high/low  alter the dose.  
 If the trough is too high/low  alter the interval 
according to the table below: 
  
Level at 24 hours Dose Interval 
<2mcg/mL 24hr 
2.1 - 3mcg/mL 36hr* 
3.1 - 4mcg/mL 48hr* 
>4mcg/mL Consider alternative antibiotic e.g. 
cefotaxime  
* If interval >24h, discuss with paediatrician whether an alternative antibiotic is 
required  
   
Adverse Effects: Nephrotoxicity and ototoxicity may occur with gentamicin therapy.  
Administration  Gentamicin should be administered as a 3-5 
minute IV push.  
 Follow with a 2mL saline flush over 3-5 minutes.  
 Peak levels (if required) are to be taken one hour 
after administration  
Interactions:  Increased risk of nephrotoxicity with concomitant 
amphotericin, indomethacin (indometacin) and 
vancomycin.  
 Increased risk of ototoxicity with concomitant 
furosemide.  
 ß-lactam antibiotics have been associated with 
inactivation of gentamicin. This is probably only clinically 
significant when penicillin containing compounds are 
mixed in IV solutions or when the blood is at room 







3 - 5.5 
n/s, G, G10%, TPN 
For TPN & lipid compatibility, see Comments. 
Compatible: aciclovir, clindamycin, dopamine, 
fluconazole, insulin, heparin (concentrations <1u/mL), 
magnesium sulphate, meropenem, metronidazole, 
midazolam, morphine, prostaglandin E1, ranitidine 
Incompatible: amoxicillin, amphotericin, 
erythromycin, furosemide, heparin (concentrations 
>1u/mL), imipenem/cilastatin, indomethacin 
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 Store at room temperature below 25ºC. 
Notes: Ampoules are single use only. Discard unused remainder 
of ampoule after opening. 
Plugged Lines For plugged lines always administer via a separate line to the 
TPN if available. For plugged lines with no carrier fluid, give 
gentamicin as a 3-5 minute IV push, followed by a 4mL normal 
saline flush as 20 minute infusion via syringe driver. For small 
babies, be aware how much fluid is given with the gentamicin/flush, 




 Gentamicin is incompatible with lipid emulsion 
when they are mixed together, but available evidence 
suggests terminal injection site compatibility.  
 It is preferred that gentamicin be administered via 
a separate line to the TPN ± lipid. If this is not possible, 
administer via three way tap site closest to baby. The 
dose must go through a 0.22-micron filter regardless of 
where it is administered in the overall line set-up.  
 If other infusions of drug are running e.g. 
morphine, make sure these are not moved through too 




Scope of Practice: Ensure you are fully qualified to perform the role specified in any document. 
Deviations: If you need to deviate from any procedure, policy, or guideline, make notes and follow up. 
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